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Smyd1 is the founder of a gene family whose members contain split SET and MYND 
Domains.  Smyd1 has several SET dependent lysine methyl-transferase substrates, 
including multiple histone lysines and at least one non-histone protein, skNAC.  The 
MYND domain of Smyd1 is required for protein interactions, such as that with skNAC.  
Conventional Smyd1 knockouts die at E10 due to cardiac defects, including an 
enrichment of cardiac jelly, a decrease in trabeculation, and the loss of ventricular 
septation.  dHand, a transcription factor specific for right ventricular development, and 
Irx4, a ventricle specific gene, are down regulated. 
I have shown that an approximately one kb stretch of DNA sequence upstream of the 
muscle specific first exon of Smyd1 is sufficient to drive expression of a reporter in 
transgenic mice.  Cardiac specific expression is mediated by a proximal Mef2 binding site 
whereas skeletal muscle expression is dependent on E-boxes.  I have fully analyzed this 
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stretch of sequence via computational methods and made predictions on other potential 
regulatory factors.   
Through the use of Cre mediated conditional knockouts, I have shown that the 
phenotype of the conventional knockout was not due to the introduction of the Neomycin 
cassette at the gene locus or due to cell non-autonomous effects on the heart.  Smyd1 is 
not only essential for cardiac septation, but throughout embryonic cardiac development, 
during embryonic skeletal muscle development, and in adult cardiac tissue.  
Conditionally deficient Smyd1 embryonic hearts are less affected than conventional 
Smyd1 knockouts, but are embryonically lethal and show poor trabeculation, cardiac 
hemorrhaging, and a pericardial edema.  I detail that the Nkx2.5-Cre mediated Smyd1 
deletion phenocopies the skNAC conventional knockout and that both knockouts have 
similar changes in the expression levels of several genes.  Furthermore, when Smyd1 is 
conditionally removed from adult cardiac tissue, survival rates are diminished. 
Surprisingly a skeletal muscle specific CKO of Smyd1 mediated by Myogenin-Cre 
has resulted in perinatal lethality, with a visible phenotype as early as E15.  Evident in the 
phenotype is a large edema between the epithelium and skeletal muscle, fewer myoblasts, 
decreased muscle mass, increased degenerating cells, and a potentially defective 
differentiation process. 
 viii
Table of Contents 
List of Tables ...........................................................................................................x 
List of Figures ........................................................................................................ xi 
Chapter 1  Introduction and Background.................................................................1 
1.1  Smyd1 Discovery, Gene Layout, and Expression Pattern........................1 
1.2  Smyd Domains and Their Functions ........................................................3 
1.3  Important Players Regulating Cardiac and Skeletal Muscle Development 
and Disease ............................................................................................6 
1.4  Rationale and Preview ...........................................................................10 
Chapter 2  Materials and Methods .........................................................................12 
2.1  Computational Promoter Analysis.........................................................12 
2.2  Promoter Constructs...............................................................................12 
2.3  Transgenic Mice.....................................................................................13 
2.4  X-gal Staining ........................................................................................13 
2.5  Smyd1 Flox Vector and Targeting .........................................................13 
2.6  PCR genotyping.....................................................................................14 
2.7  Recombination Assays...........................................................................17 
2.8  Timed Matings and Mouse Husbandry..................................................18 
2.9  Drug Administration ..............................................................................18 
2.10 Tissue Harvest and Preparations for Paraffin Sectioning .....................19 
2.11 Tissue Harvest for RNA Extraction......................................................20 
2.12 skNAC Knockout...................................................................................20 
2.13 Microarrays ...........................................................................................21 
2.14 RT-PCR.................................................................................................21 
Chapter 3  Transcriptional Regulation of Smyd1 Expression ................................23 
Chapter 4  Smyd1 is Essential in All Stages of Embryonic Cardiac Development….
.......................................................................................................................46 
4.1  The EIIA-Cre induced Smyd1 knockout recapitulates the conventional 
Smyd1 KO ............................................................................................50 
 ix
4.2  The Nkx2.5-Cre mediated Smyd1 knockout demonstrates that Smyd1 is 
essential post ventricular septation. .....................................................54 
4.3  αMHC-cre induced recombination of the Smyd1Flox locus occurs in the heart 
and gonad tissues and is embryonically lethal.....................................65 
4.4  Discussion ..............................................................................................69 
Chapter 5  MyoG-Cre Induced Embryonic Skeletal Muscle Smyd1 Knockouts are 
Embryonic Lethal with Few Observed Changes in the Transcriptome. .......71 
Chapter 6  Adult Inducible Smyd1 Knockouts Suggest that Smyd1 Functions in 
Muscle Maintenance Pathways as well as Developmental Pathways. .........90 
6.1  αMHC-cre-PR1 mediated  Smyd1 adult heart conditional knockouts suffer 
premature lethality, likely from chronic heart failure..........................90 
6.2  Smyd1 adult skeletal muscle inducible knockout mediated by MLC-rtTA 
and Tet-On-Cre is not effective in all skeletal muscle tissues. ..........107 
Chapter 7  Identification of Previously Uncharacterized Smyd1 Alternative Splice 
Isoforms ......................................................................................................111 
Chapter 8  Discussion ..........................................................................................116 
Appendix 1  Alphabetical Listing of all Transcription Factor Binding Site Hits on 1kb 
of mmSmyd1 putative promoter..................................................................119 




List of Tables 
Table 4.1  Nkx2.5-Cre induced Smyd1 CKOs are not viable.................................61 
Table 4.2  αMHC-cre induced recombination of Smyd1 is not viable ..................68 
Table 5.1  Skeletal Muscle specific knock-down of Smyd1 is lethal prior to weaning.
...........................................................................................................75 





List of Figures 
 
Figure 1.1  Smyd1 is a gene that encodes three isoforms.........................................2 
Figure 2.1  PCR Genotyping Schematic.  .............................................................16 
Figure 3.1  Human and Mouse Smyd1 Regulatory Region Alignment..................27 
Figure 3.2  Several Motifs are conserved beteween mmSmyd1, hsSMYD1, and 
mmDesmin, but not with mmHop.....................................................34 
Figure 3.3  Time progression of reporter expression of a 1kb regulatory region 
directly upstream of Smyd1...............................................................35 
Figure 3.4  Promoter Reporter Constructs in the Promoterless AUG Background…
...........................................................................................................36 
Figure 3.5  Promoter Reporter Constructs Fused to a Basal Heat Shock Promoter...
...........................................................................................................37 
Figure 3.6  Expression in the 1kb promoterless constructs is much weaker than 
expression in the 700 bp Hsp promoter constructs. ..........................38 
Figure 3.7  Expression patterns of transgenes directed by distal (–3303/+196) and 
proximal (–637/+196) regulatory regions of Smyd1 at E11.5. .........39 
Figure 3.8  A Mef2-binding site is required for cardiac expression of Smyd1.......40 
Figure 3.9  E-boxes are required for Smyd1 expression in developing skeletal muscle.
...........................................................................................................41 
Figure 3.10  A comprehensive prediction of important mmSmyd1 promoter binding 
sites. ..................................................................................................45 
Figure 4.1  Targeting strategy of Smyd1 Flox allele..............................................49 
Figure 4.2  Possible LoxP recombination events...................................................52 
 xii
Figure 4.3  Smyd1ΔKI/ΔKI phenocopies Smyd1KO/KO. ...............................................53 
Figure 4.4  Nkx2.5-Cre Mediated Recombination of Smyd1Flox allele is detected only 
in the heart.........................................................................................57 
Figure 4.5  When Smyd1Flox is combined with Nkx2.5-Cre, Smyd1 is effectively 
knocked down and mice display an embryonically lethal cardiac 
phenotype..........................................................................................58 
Figure 4.6  The 17 characterized gene targets discovered in microarrays of the skNAC 
knockout were confirmed to be differentially expressed in both the 
skNAC knockout and the Smyd1 knockdown....................................64 
Figure 4.7  αMHC-cre induced recombination of Smyd1 occurs in the heart and 
gonads. ..............................................................................................68 
Figure  5.1  MyoG-Cre induces recombination of Smyd1 specifically in muscle tissue.
...........................................................................................................72 
Figure 5.2  Skeletal muscle development in the MyoG-Cre induced Smyd1 CKO is 
significantly derailed by E15.5. ........................................................76 
Figure 5.3  Proliferation of Skeletal Muscle in MyoG-Cre induced Smyd1 knockouts 
is unaffected, but there are non-autonomous effects on BAT. .........77 
Figure 5.4  Skeletal Muscle Smyd1 deficiency does not affect transcription levels of 
MRFs (Myogenic Regulatory Factors). ............................................80 
Figure 5.5  Transcript levels of TNFα and IL6 vary in Smyd1 deficient skeletal muscle
...........................................................................................................81 
Figure 5.6  A heritable change has occurred in a portion of the skeletal muscle 
specific Smyd1 CKO mouse line allowing CKOs to survive............84 
Figure 5.7  Recombination is occurring specifically in the skeletal muscle of the 
MyoG-Cre positive Smyd1Flox/Flox survivors. ....................................85 
 xiii
Figure 5.8  Slow/Fast fiber type composition is altered in adult Smyd1 deficient 
skeletal muscle. .................................................................................86 
Figure 6.1  αMHC-crePR1 induces recombination of the Smyd1Flox allele at varying 
levels specific to the heart.................................................................94 
Figure 6.2 Mice with αMHC-cre-PR1 mediated Smyd1 deficiency have reduced life 
expectancies. .....................................................................................95 
Figure 6.3  The total population shows a normal Gaussian distribution of time of 
death, but when divided based on gender, the curves shift in opposite 
directions...........................................................................................96 
Figure 6.4  The curves associated with male or female deaths do not show the same 
pattern. ..............................................................................................97 
Figure 6.5  Smyd1 is significantly knocked down before death occurs. ................98 
Figure 6.6  The percent heart weight to total body weight is not significantly changed, 
but is deregulated. .............................................................................99 
Figure 6.7  The heart weight is significantly changed in pooled 34 week old mice…
.........................................................................................................100 
Figure 6.8   Hearts of conditional knockout mice are larger, with increased ventricular 
chamber diameters, and decreased wall thickness, but no defects in the 
gross muscle structure.....................................................................101 
Figure 6.9  Hand2, Kcnd2, and IL6 transcripts are deregulated in Smyd1 deficient 
hearts. ..............................................................................................104 
Figure 6.10  Phenotypic Smyd1 CKOs have significantly decreased levels of Smyd1 
increased levels of natriuretic peptides and decreased levels of skNAC 
and Kcnd2 in both ventricles...........................................................105 
 xiv
Figure 6.11  Animals treated with Doxycycline have a significant Smyd1 knockdown 
in the forelimb, but not the hindlimb. .............................................109 
Figure 7.1  With the exception of the adult heart, where Smyd1 alternative splice 
forms exist endogenously, the previously undocumented transcripts exist 
only in the presence of the Smyd1 deficient alleles.........................113 
Figure 7.2  Although, the Smyd1 monoclonal antibody detects Smyd1 splice variant 
encoded proteins, there is no evidence to suggest these proteins are 
expressed in vivo. ............................................................................114 
 1
Chapter 1. Introduction and Background 
 
1.1  Smyd1 Discovery, Gene Layout, and Expression Pattern 
During the process of studying the CD8β locus, a novel transcript was discovered 
that initiated at the same locus.  This transcript belonged to a gene that initiated 200bp 
upstream of CD8β in the opposite orientation.  This gene was entitled Bop for CD8β 
opposite and was later renamed Smyd1 (SET and MYND Domains), the founder of a 
evolutionarily distinct family of genes containing a SET domain split by a MYND 
domain. 
Initial studies determined that the mouse Smyd1 encoded 3 alternatively spliced 
isoforms: Smyd1a, Smyd1b, and Smyd1c (Fig. 1.1).  Smyd1c has a unique first exon (exon 
1a) including both 5’UTR and coding sequence; Smyd1c also has a unique 3’UTR.  
Smyd1a and b exclude exon 1a and initiate at exon 1b, which is separated from exon1a by 
a 70kb intron.  Smyd1a and b differ only by the small 39 base pair exon 5 that is included 
in Smyd1a and c, but excluded from Smyd1b.  Transcripts from Smyd1a and b are 
restricted to cardiac and skeletal muscle in embryonic and adult tissue while Smyd1c is 
specific for thymocytes in adult and embryonic tissue.  
Because the initial coding exons are distinct and separated by such a vast intron, it 
is logical that the regulatory regions are encoded by different sequences.  Given the 
proximity to one another, Smyd1c is likely co-regulated with CD8β.  It is expected that 
the regulatory region of the muscle specific isoforms functions independently of other 
genes and is adjacent to exon 1b.  In other words, it is likely that motifs within this region 
are responsible for gene activation and repression in cardiac and skeletal muscle tissue.   
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Fig 1.1  Smyd1 Genomic Structure 
 
 
Figure 1.1  Smyd1 is a gene that encodes three isoforms.  The upper panel 
illustrates the genomic context of the Smyd1 gene and the three characterized 
splice isoforms.  The lower panel describes the three proteins.  Smyd1a and b are 
expressed specifically in skeletal and cardiac muscle.  Smyd1c has an alternative 
first exon and is expressed specifically in thymus.  Both first exons are separated 
by a very large intron.  The first exon for Smyd1c is directly adjacent to the 
CD8β gene.  Smyd1c has a distinct 5’ and 3’ UTR. 
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1.2  Smyd Domains and their functions 
SET Domain 
Smyd defines a family of proteins that contain a split SET and a MYND domain.  
These domains are suggestive of Smyd function.  Many SET domain containing proteins 
have been found to function as histone lysine methyl transferases, or HKMTases, such as 
SUV39H1, G9a, and Clr4.  HKMTases can transfer one or more methyl groups onto 
specific lysine residues on histone tails.  Five lysine residues have been discovered and 
characterized, including histone 3 lysine 4 (H3K4), histone 3 lysine 9 (H3K9), histone 3 
lysine 27 (H3K27), histone 3 lysine 36 (H3K36), and histone 4 lysine 20 (H4K20).  The 
histone core residue H3K79 has also been been characterized, although it is not present 
on histone tails.  Methylation of H3K4, H3K36, and H3K79 are associated with 
transcriptional activation while methylation of H3K9 and H3K27 are associated with 
transcriptional repression [1].  H4K20 methylation has been implicated in DNA repair[1], 
DNA silencing [2], as well as the governing of the myogenic program [2].   
Smyd1 has been shown in vitro to methylate multiple histone substrates, including 
H3K4, a novel mark on H4, and at least one non-histone substrate, skNAC [3].  Several 
HKMTases have recently been shown to have non-histone targets.  Set 9, which has long 
been known to methylate H3K4, Smyd2, which has recently been shown to methylate 
H3K36 [5] and H3K4 [4], and Set8, which is known to methylate H4K20 [5], have both 
recently been shown to methylate specific residues on p53 [7-9].   However, it is still 
unusual for SET domains to have multiple histone residue and non-histone targets.  
Because the SET domain of Smyd proteins is interrupted by another domain, the 
specificity of the SET domain may be sacrificed causing Smyd proteins to have multiple 
specific histone targets or it may simply lead to an artificial promiscuity in vitro.  
Therefore, despite knowing 3 in vitro methylation targets for Smyd1, there are questions 
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as to which, if any, are true in vivo methylation targets and whether the most biologically 
significant methylation targets have been identified.   
 
MYND Domain 
The MYND domain has been very broadly implicated in protein-protein 
interactions through a PXLXP motif.  Smyd1 is most homologous to the MYND domain 
of ETO [10].  Like ETO, Smyd1 binds directly to class I and class II HDACs, although 
this activity is independent of the MYND domain [6].  Smyd1 associates with multiple 
repression complexes that include N-CoR and Sin3.  Immunoprecipitation of N-CoR by 
Smyd1 is dependent on the MYND domain [6].  skNAC is the most common Smyd1 
interacting partner pulled out of yeast 2-hybrid screens with both cardiac and skeletal 
muscle libraries [6, 7] and has been shown to bind specifically via a PXLXP motif to the 
MYND domain of Smyd1 [8].  Through specific DNA binding at the promoter, skNAC 
has been reported to co-activate transcription of Myoglobin, a gene important for 
transporting and regulating oxygen levels in muscle tissue [9].  Other potentially 
interesting Smyd1 interacting factors that bind through the MYND domain include 
FKBP506(8), a regulator of NFAT and calcineurin; and TRB3,which is involved in 
insulin resistance [7]. 
 
Protein Function 
Gal4-Smyd1 fusion proteins repress transcriptional activity of a LexA-VP16 
activated Luciferase reporter [10].  Repression activity is inhibited by mutations of the 
conserved cysteines in the MYND domain [6] or by addition of TSA, an HDAC inhibitor 
[10].  Although Smyd1 is a transcriptional repressor when ectopically forced to bind DNA 
through Gal-4 domains, it may act differently when it is recruited to DNA in the 
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endogenous context.  When the reporter system is co-transfected with the Smyd1-Gal4 
fusion proteins and EBNA2, a PXLXP containing oncogene, Smyd1b activates expression 
of a Luciferase reporter (Personal Communication, R.J. Sims).  While this experiment 
does not provide an endogenous context, it supports the hypothesis that Smyd1 proteins 
will act differently in different contexts.  Therefore, it is likely that when Smyd1 is in 
specific complexes it acts to repress its target genes, but when found in other complexes, 
Smyd1 may act to activate its target genes.  This activity may be dependent on which 
histones are modified or which factors are bound to either the Smyd1 protein or the DNA 
locus to which Smyd1 is recruited.  It may also be dependent on the specific expression 
patterns of co-activators or co-repressors.  Dual roles could be part of a muscular 
checkpoint control mechanism; it could play a role in regulating chamber specific protein 
expression in the heart; or allow Smyd1 to play different roles in temporal and spatial 
specific manners.   
Little is known about the mechanism through which Smyd1 functions, however, 
conserved SET and MYND domains, interaction studies, and reporter assays suggest that 
the 3 isoforms of Smyd1 act as transcriptional factors by targeting histones or non-histone 
proteins for deacetylation and/or methylation.  It seems likely that there are distinct roles 
and functional differences for Smyd1a and Smyd1b.  In Smyd1a, the short 39 base pair 
exon 5 interrupts the C-terminal portion of the SET domain.  Because Smyd1b, lacks 
exon 5 and more closely resembles a SET domain, most biochemical work thus far has 
focused on Smyd1b.  However, when independently over expressed in C2C12, an 
immortal myoblast cell line, only Smyd1b methylates skNAC and effects Myoglobin 
transcript levels [3].  It is possible that these isoforms have differing roles in temporal and 
tissue specific contexts, but this has not been measured due to difficulty distinguishing 
both the transcripts and the proteins.  
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1.3 Important Players Regulating Cardiac and Skeletal Muscle Development and 
Disease 
Cardiac Development  
During development of all vertebrates, the heart is the first organ to undergo 
organogenesis and is essential for the proper development of all other organs.  Every year 
36,000 American infants, almost 1% of annual births, are expected to suffer from 
congenital cardiac defects [11].  Although almost as many people born with congenital 
cardiac defects survive at least until the age of 25, this group of birth defects leads to 
more infant deaths than any other birth defect [11].   
The morphological changes in the developing heart are well understood.  This is a 
complex process that requires precise timing of cell migration, myogenesis, 
morphogenesis and contractility.  In murine heart development, the primary heart field 
forms a crescent during gastrulation that fuses into the linear heart tube at E8.0.  At this 
point, the heart begins to beat and is essential for continued embryonic development.  The 
proliferating secondary heart field migrates into the heart tube, causes it to loop to the 
right, and contributes to the right ventricle, inflow tract, and outflow tract [12-14].  The 
heart loop segments into atrial and ventricular chambers.  After segmentation, the 
ventricular chambers must undergo compaction and trabeculation in order to maintain the 
necessary hemodynamic pressure while both atrial and ventricular chambers further 
septate to create the mature four chambered heart [15].   
Nkx2.5, homologous to the drosophila gene tinman, and one of the earliest 
markers of cardiomyocyte populations, has been well studied and was the first putative 
regulator of the cardiogenic program [16].  However, while knockouts of Nkx2.5 were 
striking, the effect was primarily on morphogenesis and the ventricular chambers [16].  It 
has recently been shown that GATA-4 is sufficient to induce cardiomyogenesis [17] and 
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is hypothesized to work synergistically with SMAD proteins to activate Nkx2.5 [18].  
However, what is known about the molecular pathways governing cardiac development is 
not much more than a laundry list of critical transcription factors for distinct processes.  
The first known marker of cardiomyocytes is MesP1, which is first expressed E6.5 and is 
critical for proper cell migration into the cardiac crescent [19].  Nkx2.5 is thought to play 
a role in regionalization, or chamber specification [20].  Tbx5 and Mlc2a are essential for 
atrial development [21, 22].  Mlc2v specifically marks the ventricular myocardium [23].  
Isl1 is a known marker of the secondary heart field, which is thought to provide the 
majority of the cells for the right ventricle [24].  Hand2,or dHand, is essential for right 
ventricular development and Hand1, or eHand, primarily expressed in the left ventricle, 
is essential for cardiac looping [25].  Many different signaling pathways have been 
implicated in different compartmentalized aspects of cardiac development, including the 
TGFβ/BMP signaling cascade [12, 22, 26-29].  There are multitudes of individual genes 
known to play a role in cardiogenesis, but there is no clear consensus in the field on a 
hierarchical molecular pathway that regulates the complex process after the initial 
migration and fating of the early cardiac crescent. 
Heterozygotes for Smyd1 are completely viable and normal.  However, 
homozygotes for the Smyd1 knockout are embryonic lethal at E9.5, approximately 
halfway through gestation.  At this stage, the null mutant has an enlarged left ventricular 
chamber with an excess of extracellular matrix (ECM) and is completely void of the right 
ventricle [10].  In the Smyd1 null mice, expression of Mlc2a, Mlc2v, Nkx 2.5, and Tbx5 
transcripts were normal.  However, Hand2 expression is ablated and expression of the 




Skeletal Muscle Development  
Unlike the cardiac muscle, skeletal muscle is not necessary during development; 
skeletal muscle is necessary in order to breathe and feed at and after birth.  In mice, 
skeletal muscle is also essential for locomotion necessary in order to compete with 
littermates during the nursing stage.  Myogenic Regulatory Factors (MRFs), including 
Myf5, Myf6/Mrf4, MyoD, and Myogenin (MyoG), have long been thought to direct and 
control muscle development.  Surprisingly, however, single MRF mouse knockouts have 
had only marginal effects on myogenesis with one exception, the MyoG knockout, whose 
deficiency results in a normal number of myoblasts that are incapable of differentiating 
into myotubes [30, 31].  This argues that MyoG is essential for myogenic differentiation 
process.   
Double knockouts of MyoD and Myf5 have a large impact on myogenesis, 
suggesting that these two genes share redundant pathways and are overlapping in 
function.  In this double knockout, mice are born, but fail to move or survive past birth.  
There are no detectable myoblasts or myoblast-like cells suggesting that MyoD and Myf5 
play a partially redundant role in cell fate determination and the commitment to a 
myogenic fate [32].   
Myf6 is expressed in a biphasic pattern including myotome restricted expression 
during embryonic day 9 through 11 and in all skeletal muscles from embryonic day 16 
until after birth [33].  Myf6 knockouts have not yielded straight forward data.  However, 
it was discovered that alterations at the Myf5 locus or Myf6 locus have affects on both 
genes [34].  It has thereby been shown that the early phase of Myf6 expression is 
important for skeletal muscle fate determination [34].  It is still thought that the second 
phase of Myf6 expression has an important role in organizing and maintaining 
differentiated myotubes.  
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Adult Cardiac Disease 
Even after development, the heart is one of the most vital organs.  When the heart 
malfunctions other organs cannot continue normally.  A malfunctioning heart’s owner 
has decreased quality of life and life expectancy.  One in three adults in the United States 
suffer from at least one type of cardiovascular disease ranging from hypertension to 
cardiac failure [11].  Therefore, the molecular signals that either induce cardiac disease or 
maintain healthy cardiac tissue are very intriguing subjects.  Smyd1 has been correlated 
to cardiac ventricular diseases and to the maintenance of the ion gradients required for a 
normal heart beat. 
A study performed on explanted diseased human hearts discovered that Smyd1 is  
two or three fold over expressed in diseased left and right ventricles, respectively, 
compared to biopsies of the healthy transplanted hearts [35].  However, like many of the 
ion-channel genes analyzed in this study, expression of Smyd1 was normal in explanted 
hearts that had been treated with a left ventricular assist device (LVAD) [35], which is a 
surgically implanted mechanical pump.  This pump helps keep blood circulating, relieves 
hemodynamic pressure on the ventricle, and helps extend life expectancy for those on 
heart transplant waitlists.  Therefore, Smyd1 transcription is activated directly or 
indirectly by mechanical stress.  Smyd1 transcript levels return to normal in response to 
alleviation of that stress via LVAD implantation.  However, it is unclear whether the role 
of Smyd1 is to cause or overcome cardiac disease. 
Atrial and brain naturietic peptides (ANP and BNP) are established markers for 
many cardiac diseases, particularly chronic heart failure and left ventricular dysfunction 
in human patients [36-39] and experimental rat models of myocardial infarction [36, 40].  
Both are secreted in response to the mechanical stress of atrial or ventricular wall 
stretching [39].  ANP is thought to inhibit growth and proliferation [40] while BNP is 
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thought to induce myocardial relaxation [39].  Levels of ANP and BNP transcripts are 
directly correlated to the severity of heart failure [41].  Neither of these markers are 
returned to normal levels in LVAD treated patients [35]. 
In wildtype mice, Kcnd2, the gene encoding the Kv4.2 potassium channel α-
subunit, is expressed differentially in the ventricular epicardium and endocardium 
resulting in a potassium gradient that is necessary for a stable heart beat.  A recent study 
has shown that Smyd1 and Irx5 directly interact in order to regulate Kcnd2 transcription 
[42].  When Smyd1 is expressed in an Irx5 null situation, Kcnd2 is activated, but when 
Irx5 or Smyd1 are combined, activation of Kcnd2 transcription is inhibited [42].  Irx5 is 
endogenously expressed in an inverse gradient to Kcnd2, whereas Smyd1 is expressed 
throughout the heart.  This Kcnd2 gradient could be caused and exaggerated if Smyd1 
activates Kcnd2 in Irx5 deficient zones and inhibits Kcnd2 in Irx5 positive zones.  In 
mice null for Irx5, Kcnd2 expression is equal in the ventricular epicardium and 
endocardium and tachycardia is more easily induced [42]. 
 
1.4 Rationale and Preview 
In order to determine which pathways Smyd1 is involved and to prove that 
Smyd1a and b were regulated by independent regulatory regions from Smyd1c, we 
analyzed the putative regulatory region for functionality and tissue specificity by using 
transgenic promoter-reporter studies.  During the course of this study, I have analyzed the 
putative Smyd1 regulatory regions for candidates that likely regulate Smyd1 transcription.  
Some of these have been tested in vivo by using transgenic mutant promoter-reporter 
technologies.  The others have been chronicled for use in later studies. 
To determine what role Smyd1 plays throughout cardiac development, during 
skeletal muscle development, and in adult maintenance of the two tissues, I have induced 
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the Smyd1 knockout in each system independently using Cre-LoxP technologies.  I have 
analyzed the phenotype in each tissue to determine likely pathways and processes with 
which Smyd1 may be involved. 
The data is reported in four chapters.  Chapter 3 describes work done on the 
Smyd1 promoter.  Chapter 4 describes the three embryonic heart specific conditional 
knockouts.  The fifth chapter discusses the embryonic skeletal muscle conditional 
knockout.  Adult conditional knockouts were discussed in chapter six.  Observations 
detailing the presence of novel alternative splice forms and the potential impact on 
previous data were discussed in a short seventh chapter.  Conclusions drawn from each 
section were discussed within the relevant chapters.  A discussion chapter was included 
to address concepts that were not contained within one specific chapter. 
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 Chapter 2.  Materials and Methods 
 
2.1  Computational Promoter Analysis 
The regions immediately upstream of the Smyd1 coding region from the mouse 
and human genomes were identified by blasting the coding sequences obtained from the 
National Center for BioInformatics (NCBI) for human and mouse Smyd1 against the 
respective genome databases.  The 3kb regions 5’ to the first exon of the skeletal and 
cardiac muscle Smyd1 isoform were identified in each genome, resulting in 2 sequences.  
These sequence were compared using 2-sequence blast program (NCBI) and Genomatix 
promoter software to identify conserved DNA regions and conserved protein binding 
sites that may affect transcriptional regulation of Smyd1. 
 
2.2  Promoter Constructs 
In order to obtain wildtype sequence from the Smyd1 locus, Incyte Genomic, Inc. 
screened BAC libraries and provided three positive clones.  One of these resulting clones, 
BAC 26242, contained the entire Smyd1 locus.  This was digested using XbaI and the 
resulting fragments were ligated into pBlueScript.  From this XbaI library, clone BAC42-
Xba9 was isolated and used as a template for creating wildtype promoter-reporter vectors 
for mouse transgenic expression.   
The 0.5kb promoter construct was created by ligating a PCR product made using 
Vent polymerase, the BAC42-Xba9 template, and the following primers: mBOPPROF 
ctcagagtctgtcaggccttcg and mBop 0.5kb Rev ggagacactagggtgggg into the SmaI site of 
pBSSKAUG-bGalXSal, obtained from Ellen Lien and created by Doris Brown.  The 1kb 
promoter construct was created in the same manner, except primer mBop 0.5kb Rev was 
replaced with the primer Bop Xba-9 Rev: gaactgtgagggtcacactc.  The 3kb promoter 
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construct was created by digesting BAC42-Xba9 with BamHI and inserting the resulting 
3.2kb fragment into BamHI digested 0.5kb construct and screening for orientation.   
Mutations were created by PCR mutagenesis using the 1kb promoter as a template 
for the following sites: Myf5 c436a, a435g; Mef2 t399g, g404c; MyoD t733c; Mef2 
a999g, a998g.  These were all created by following the protocol provided with the Gene 
Editor Site Directed Mutagenesis Kit (Promega) and confirmed by DNA sequencing. 
 
2.3  Transgenic Mice 
Constructs were digested with XhoI and NotI to create a linear fragment of 4.9kb, 
5.4kb, and 7.8kb, respectively.  The wild type linear fragments were cleaned by passing 
over a Qiagen Miniprep column and injected into fertilized oocytes of B6C3F1 female 
mice.  These were implanted into pseudopregnant ICR mice as previously described [43].  
24 founding lines were created. 
 
2.4  X-gal Staining 
Transgenic male mice were timed mated, as described below, to wildtype DB2 
females.  At various ages of development (8.5 through 15.5dpc), the embryos were 
dissected and LacZ expression was detected by staining with X-gal, as previously 
described [44].  Stained embryos were fixed in 4% paraformaldehyde at 4oC overnight 
prior to paraffin sectioning, as previously described [44]. 
 
2.5  Smyd1 Flox Vector and Targeting 
Endogenous sequence was obtained from a Lambda FixII Vector 129SV Mouse 
Genomic Library (Stratagene).  The targeting construct was designed in the Osdupdel 
vector, a gift from William A Kuziel, in order to introduce LoxP sites flanking the second 
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and the third exons of Smyd1 followed by a neomycin cassette that is flanked by a third 
LoxP site.   The targeting vector was electroporated into 129S6 ES cells.  After selecting 
with G418 and gancyclovir, surviving clones were screened for homologous 
recombination by Southern analysis after digestion either with Bgl II and Sal I or Bgl II 
and Kpn I, and hybridization with probe 2 and probe 3, respectively.   
ES clones showing correct targeting in both arms were injected into C57BL/6 
blastocysts to create chimeric mice.  The chimeric mice were mated to C57BL/6 females 
to create a germline knock-in referred to as Smyd1KI.  Smyd1KI mice, B6.129 hybrids, 
were crossed to ubiquitously expressing EIIa-Cre mice, B6.FVB hybrids, and progeny 
were screened for deletion of the neomycin cassette by Southern analysis and back-
crossed in order to remove EIIa-Cre.  Resulting Smyd1Flox mice lacking EIIa-Cre were 
crossed with several transgenic Cre lines including Nkx2.5-Cre, MyoG-cre, aMHCcre, 
αMHC-CrePR1, and MLC-rtTA, and Tet-ON-Cre.   
 
2.6 PCR genotyping 
At weaning, each mouse was given a unique ear punch and a short piece of tail (2-
5mm) was biopsied.  The tail tissue was cooked overnight at 55oC to 60oC in 200ul Tail 
PCR Buffer (50mM KCl, 10mM Tris (pH8.3), 2.5mM MgCl2, 0.1mg/ml gelatin, 0.45% 
v/v NP40, 0.45% v/v Tween 20) plus 2ul Proteinase K (10mg/mL), boiled for 5 minutes 
and centrifuged for 10 minutes.  3-5ul of this solution was used in each genotypic PCR 
reaction.  PCR conditions were as follows: step 1) 94oC 5min, Step 2) 94oC 30s, Step 3) 
62oC for 1min, Step 4) 72oC 1min, Step 5) Go To step 2- 29 times, Step 6) 72 oC 7 min, 
Step 7) 4oC for ever.  The primers KO7S: cacatctttggtgtggtatggc and KO8AS: 
ctcacttgcgtcccagtacttg detect Smyd1WT (540bp) and Smyd1Flox (620bp).  Alternatively, 
primers KO5AS: gcatacgcacatgtgctcgc and KO4S: tcatgagatgggcatgagcc detect Smyd1WT 
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(432 bp) and Smyd1Flox (552 bp) (Fig. 2.1).  Genotyping primers KO4S: 
tcatgagatgggcatgagcc and WAK65: gcccggttctttttgtcaagaccga detect Smyd1KO and yield a 
product predicted at 985bp, but that runs at approximately 850bp.  Genotyping primers 





Fig 2.1  PCR  Genotyping Schematic.  Primers have been designed to flank the targeted 
knock-in LoxP sites in a manner that distinguishes several Smyd1 alleles.  KO5AS/KO4S 
and KO8AS/KO7S are two primer pairs that detect Smyd1WT and Smyd1Flox at varying 
sizes.  Primers internal to the LoxP sites have been deleted from Smyd1Floxdel, Smyd1KO, 
and Smyd1KOR.  The external primers can be used to detect the recombination products, 
Smyd1Floxdel and Smyd1KOR.  Primers internal to the neomycin cassette are paired with 
endogenous primers to detect the Smyd1KOallele.
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2.7 Recombination Assays 
Recombination in each cross was determined by PCR genotyping to determine 
tissue specificity and efficiency of deletion.  Heterozygous mice (Smyd1Flox/WT; XX-
Cre+/?) were sacrificed and tissues were harvested into eppendorf tubes.  Tissue samples 
were incubated at 55-60oC in 430ul Southern Tail PCR Buffer (50mM Tris pH 8.0, 
100mM EDTA, 100mM NaCl, 1%SDS) and 70ul proteinase K (10mg/ml).   After 
complete digestion of the tissue (16-48 hours), samples were phenol:chloroform 
extracted.  Briefly, 500ul of phenol was added to each sample, vortexed for 30 seconds 
and centrifuged at full speed in a microcentrifuge for 5 minutes.  The upper aqueous 
phase was removed and the above procedure was repeated with 
Phenol:isoamyl:Chloroform (25:1:24) and Chloroform.  The third aqueous phase was 
removed and precipitated with 166ul of 30% PEG/1.5MNaCl at -80oC for 15 minutes.  
After precipitation the samples were centrifuged at full speed in a microcentrifuge for 15 
minutes, the supernatant was discarded, and the pellet was washed in 70% ethanol.  This 
pellet was then dried and resuspended in 100ul of water at 37oC.   
0.1 to 5ul of sample were used for genomic PCR using the following program:  
step 1) 94oC 5’, Step 2) 94oC 30s, Step 3) 62oC for 1min, Step 4) 72oC 1min, Step 5) Go 
To step 2- 29 times, Step 6) 72oC 7 min, Step 7) 4oC for ever.  The primers KO7S: 
cacatctttggtgtggtatggc and KO8AS: ctcacttgcgtcccagtacttg detect Smyd1WT (540bp) and 
Smyd1Flox (620bp) and the primers KO4S: tcatgagatgggcatgagcc and KO5AS: 
gcatacgcacatgtgctcgc detect Smyd1WT (432 bp) and Smyd1Flox (552 bp).  KO8AS and 





2.8  Timed Matings and Mouse Husbandry 
Originally, mice were mated with the following non-gender specific scheme, 
Smyd1KO/Flox by Smyd1Flox/WT; XX-Cre+/- to yield Smyd1KO/Flox; XX-Cre+/-.    It was later 
determined that the following scheme was equally effective:  Smyd1Flox/WT; XX-Cre+/- x 
Smyd1Flox/Flox to obtain Smyd1Flox/Flox; XX-Cre+/-.  At weaning, mice were given a unique 
ear punch and approximately 5mm of tail was biopsied for genotyping.   
In order to determine phenotypes and time of embryonic lethality, female mice 
were housed with male mice.  Females were checked for plugs daily.  The observation of 
a plug was considered day 0.5.  Females were sacrificed and ovaries were removed on the 
embryonic day of interest.  Ovaries were placed in Phosphate Buffered Solution (PBS: 
137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mm KH2PO4 (pH 7.4)) or DEPC treated 
PBS immediately after removal.  Embryos were removed from the ovaries and dissected 
in PBS or DEPC PBS.  Ages were confirmed by comparing to Rugh’s Organogeny [45].  
As well as harvesting tissues of interest, a piece of embryonic tail was harvested for 
genotyping.  Embryonic genotyping was carried out in the same manner as described 
above, with the exception that tails were incubated in Tail PCR Buffer at 55-60oC for 3 to 
16 hours. 
 
2.9  Drug Administration 
RU486 
RU486, or Mifepristone (Sigma), was suspended at the appropriate concentration 
in corn oil.  This process was aided by heat and rotation in a Bambino hybridization oven.  
Doses of 1.25 to 10mg in a volume of 0.1 to 0.3ccs were injected intraperitoneally into 




300mg of Doxycycline hydrochloride (Sigma) was mixed with 50g of ground 
mouse feed and 2.5g sucrose.  Approximately 50-60mL of deionized water was added.  
The food was rolled into pellets and kept in the dark at 4oC for up to a week.  Pellets were 
also made with only ground mouse feed, sucrose, and water for use as a negative control.  
Mice were given prepared food for 3 to 5 days with no alternative food sources. 
 
2.10  Tissue Harvest and Preparations for Paraffin Sections 
RNA Competancy/In Situ Hybridization 
Embryos at 15.5dpc or younger were extracted in DEPC PBS (1mLDEPC/L, 
autoclaved).  A piece of tail was removed for genotyping.   The remainder of the embryo 
was fixed in at least 10 fold volumes of 4% paraformaldehyde at 4oC on a nutator 
overnight.  They were then washed 3 times for at least 5 minutes in DEPC PBS and 
stored at 4oC until shipped on wet ice to UT-Southwestern or UT-Science Park for 
Paraffin embedding and tissue section as previously described [43]. 
 
Protein Competancy/Immunohistochemistry 
Embryos and adult tissues (heart) were extracted in PBS and fixed in at least 10 
fold volumes of 10% formalin or 4% paraformaldehyde at room temperature on a nutator 
for 24-72 hours.  Embryos older than 15.5dpc were skinned before fixation.  A piece of 
tail was removed before fixation and kept for genotyping.  All samples were washed 3 
times for at least 1 hour in PBS and stored at 4oC until shipped on wet ice to 
UTSouthwestern or UT Science Park for Paraffin Embedding and tissue section as 
previously described [43]. 
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2.11  Tissue Harvest for RNA Extraction 
Embryonic tissue 
Embryos were extracted as above.  For skeletal muscle, limbs were cut off at the 
shoulder and hip joints.  The wrists, ankles, and digits were removed with forceps.  The 
skin was removed from embryos older than 15dpc.  The tongue was removed by opening 
the jaw and pinching off the tongue with forceps.  Heart tissue was removed through the 
chest cavity.  Isolated tissues were immediately added to 100ul Trizol and dounced 
manually in an eppendorf tube.  After douncing, the volume was adjusted to 800ul.  A 
piece of tail was removed and kept for genotyping.  Embryonic tails were cooked at 60oC 




Whole tissue was extracted from the mouse at various time points and 
immediately added to 3mL trizol in a round bottomed polystyrene culture tube.  A piece 
of tail was removed and used to confirm the genotype.  Tissues were then homogenized 
with a polytron homogenizer at setting 22 for 1 minute at room temperature.  When the 
left and right ventricles were isolated, the left ventricle was separated from the whole 
heart with scissors.  The left ventricle and right ventricle plus septum were independently  
manually homogenized in 200ul of trizol.  After homogenization 700ul of trizol was 
added.  All trizol homogenates were stored at -80oC indefinitely.   
 
2.12  skNAC Knockout 
A targeting construct was created to replace the muscle-specific exon 2 with an 
FRT-flanked PGK-Neo cassette. Genomic fragments surrounding exon 2 of skNAC were 
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isolated by SacI digestion (6.75 kb) for the 5´ arm and XbaI digestion (1.3 kb) for the 3´ 
arm and subcloned into a vector containing a PGK-Neo cassette. The targeting construct 
was linearized with AdhI and electroporated into 129S6 ES cells. Targeted ES cells were 
selected with G418, and correct targeting was confirmed by Southern hybridization after 
HindIII and HpaI digestion with the corresponding 5´ and 3´ probes, respectively. Two 
correctly targeted ES cell clones were injected into C57BL/6 blastocysts to generate 
chimeric mice, which were bred with C57BL/6 or 129S6 mice. The offspring were 
genotyped by PCR. RT-PCR was done to test deletion of the second exon and 
preservation of αNAC expression in skNAC–/– embryos. Primers for the skNAC transcript 
were 5´-gttactgacccagcaatggctcct-3´ and 5´-tggaggagtgggagaaagcttattaag-3´. Primers for 
αNAC were 5´-cacccggtgaagccacagaaaccgtc-3´ and 5´-aactttgaatttctcagcagctgc-3´. 
 
2.13 Microarrays 
E11.5 hearts of wild type and skNAC–/– embryos were collected from timed 
pregnancies and three embryos for each genotype were processed individually for RNA 
isolation with Trizol. RNA was amplified and labeled with MessageAmp II-Biotin 
Enhanced Kit (Ambion). Affymetrix GeneChip arrays (mouse genome 430 2.0) were 
used for hybridization in triplicate.  Hybridization quality was assessed with the affyPLM 
package (Bioconductor). Preprocessing was performed with the RMA algorithm. Log-
ratios were calculated with a linear model (Limma Package, Bioconductor). 
 
2.14  RT-PCR 
Trizol homogenates were thawed and RNA was isolated following Invitrogen’s 
Trizol protocol, including the optional centrifugation to remove soluble material 
following thaw.  For embryonic samples, the isopropanol precipitation was supplemented 
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with 5-10ug of RNAse free glycogen.  After drying the RNA pellet, samples were 
resuspended in 25ul of deionized DEPC water and immediately DNase treated by adding 
15ul mix D (2.7x DNaseI buffer (Invitrogen), 1U/ul RNaseOut (Invitrogen), 2U/ul 
DNaseI (Roche)) to a final volume of 40ul and incubating at 37oC for 1 hour.  The 
enzyme was heat inactivated by adding 4ul of 25mM EDTA and incubating at 70oC for 
10 minutes.   
RNA quality and concentration was analyzed using a nanodrop 
spectrophotometer.  The same mass of total RNA (1-10ug) was used in all comparable 
samples.  5ul mix 1 (40uM oligo dT, 5.5uM dNTP) and DEPC water were combined with 
the total RNA sample to an intermediate volume of 35ul, except for the negative control, 
which was adjusted to 37ul.  Samples were boiled for 5 minutes and iced for 5 minutes 
before adding 13ul of mix 2 (3.8x 1st Strand Buffer, 20mM DTT, 1U/ul RNaseOut 
(Invitrogen)).  After prewarming the reaction mixture for 2 minutes at 37oC, 2ul of 
200U/ul MMLV (Invitrogen) was added to each reaction except the negative control.  
Samples reverse transcribed for 1.5 hours at 37oC.  The enzyme was heat inactivated at 
85oC for 5 minutes and the samples were stored at 4oC.   
1-2ul of the cDNA reaction were used for PCR with various gene primer sets.  
Reduction of Smyd1 transcripts in Smyd1Flox/Flox or Smyd1Flox/KO with Nkx2.5-Cre, MyoG-
cre, αMHC-CrePR1, and MLC-rtTA and Tet-ON-Cre was confirmed by RT-PCR.  RT-
PCR Primers most widely used for Smyd1 are 47660: ctgcgggcagtgcaagtt and Smyd1e6R: 
gctcacaggagcagtcaaagtag.  RT-PCR Primers for β-actin are β-actF: tacgagggctatgctctc 
and β-actR: cgcagctcagtaacagtc.  Other primers were designed to cross introns and are 




Chapter 3.  Transcriptional Regulation of Smyd1 Expression 
 
Transcriptional control can be regulated in concert with several genes at a given 
locus by affecting the chromatin, e.g. histone modifications that induce chromatin to be 
more or less accessible to polymerases and transcription factors.  Control can also be 
mastered at the level of individual genes by sequence dependent binding of transcription 
factors to DNA.  Because there is a 70kb intron between the thymus specific Smyd1 first 
exon, exon 1a, and the muscle specific Smyd1 first exon, exon 1b, we predicted that this 
expression pattern was derived from dual promoters.  The thymus specific first exon is 
only approximately 200 base pairs from CD8β coding sequence.  Since both of these 
transcripts share thymocyte specific expression, it is likely that factors activating and 
repressing Smyd1 transcription share the same binding sites and interacting partners with 
the CD8β locus.  However, in order to hypothesize what specifically affects the 
transcription of the muscle specific Smyd1 isoforms, the putative promoter sequence, a 
region immediately upstream of exon 1b, was analyzed for putative transcription factor 
binding sites using the genomatix software suite (www.genomatix.de), specifically, the 
MatInspector transcription factor database (see appendix 1) [46].   
 
Homology in non-coding sequences between Mouse and Human: Region 1 
The described region was then further analyzed by comparing the region in the 
mouse and human genomes (FIG 3.1).  These two genomes display a surprising amount 
of conservation in the noncoding region 600 bp upstream of the first exon of Smyd1a and 
b.  In this region interesting and conserved putative transcription factor binding sites 
include:  MTBF, TATA, Zbp-89/Maz/Sp1, Tcf11, Meis-1, and Nkx2.5.  Also, there is a 
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large cluster of conserved sequence and sites that include: MyoD/Myf5, Pbx-1/Meis-1, 
Tgif, Comp1, Mef2, and MTBF.   
 
MTBF: MyoTube Binding Factor 
MTBF is a sequence commonly found in promoters specific for myotube 
expression and was originally found between MyoD and Mef2 binding sites of the 
Desmin promoter.  This site was found to be necessary for maximal myotube 
expression of Desmin, a protein expressed specifically in skeletal muscle and 
heart [47].  It is unknown what protein(s) binds to this sequence. 
 
TATA Box:  
The TATA Box is a common element in a class II promoter and is usually found 
25 base pairs upstream of the transcription initiation site. 
 
Zbp-89/Maz/Sp1 
Zbp-89 is a ubiquitously expressed protein that has several functions, including 
DNA binding transcription factor.  Zbp-89 is thought to be capable of either 
transcriptional activation or repression.  There are at least 2 examples in which 
Zbp-89 acts as a repressor via inhibition of Sp1, either through binding site 
competition or by direct interactions [48].  There are 2 conserved Zbp-89 sites in 
the putative muscle Smyd1 promoters in mouse and human.  One of these sites 
overlaps a putative Maz binding site and the other a putative Sp1 binding site.  
Maz and Sp1 are C2H2-type zinc finger containing proteins that are known to 
bind specifically to GC-rich DNA sequences.  The consensus site for Maz and Sp1 
are very similar and, in some cases, are synonomous.  Both of these proteins are 
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thought to have repression and activation activities [49].  Hypothetically, Zbp-89 
may compete with Maz as it does with Sp1 in order to repress transcription. 
 
Tcf11 
Tcf11 is a widely expressed transcriptional activator.  The activation activity of 
Tcf11 has a dose-dependent and inverse relationship with MafG [50].  
 
Meis-1 
Meis-1 is a homeodomain protein that is a known cofactor for Hox transcriptional 
activation.  This cooperation leads to increased affinity and specificity for the 
appropriate transcriptional targets [51]. 
  
Nkx2-5 
Nkx2-5 is a pivotal transcription factor in orchestrating cardiac development.  It 
contains a homeodomain and binds directly to DNA. 
 
MyoD/Myf5 
MyoD and Myf5 are Myogenic Regulatory Factors (MRFs) that bind to DNA at E-
boxes to induce the myogenic program.  They are considered to be “master 
regulators” of myogenesis and, while they are at least partially redundant of each 
other, they are essential for myoblast determination. 
 
Pbx-1/Meis-1 
Pbx-1/Meis-1 is a binding site for a heterodimer of the two proteins.  This 
heterodimer binds DNA cooperatively with all E2a-MRF (MyoG, MyoD, Myf5, 
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Myf6) heterodimers [52].  Not only does this heterodimer enhance binding of the 
myogenic regulatory factors to E-boxes, but it is essential for binding to non-
cononical E-boxes, such as those within the Myogenin promoter [53]. 
 
Tgif: 5’TG3’ Interacting Factor 
Tgif is a homeobox protein in the TALE superclass.   It has recently been shown 
to repress transcription via a specific interaction with RXRα and the retinoid 
response element (RRE) [54].   
 
Comp1: Cooperates with Myogenic Proteins 1 
Comp1 is a protein known to bind both DNA and Myogenin and enhance the 
interaction between Myogenin and DNA containing E-box sequences [55]. 
 
Mef2: Myocyte-specific Enhancer binding Factor 2  
Mef2 was initially characterized in terms of the role in myogenesis.  It has since 
been discovered to play an important role in a wide variety of tissues.  Vertebrate 
genomes encode four Mef2 genes, A through D.  All four genes share a very 
conserved MADS domain at the N-terminus that mediates DNA binding and 
dimerization.  Mef2 proteins have a divergent region responsible for interactions 
with cofactors and a C-terminal transactivation domain [56].   
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Fig 3.1 Human and Mouse Smyd1 Regulatory Region Alignment 
SMYD1 promoter region sequence comparison; mouse to human genome; Hits on chr2:88659962-
88660712; Berkley Genome Pipeline; Bold conserved regions based on 2 sequence Blast; 
+1 based on: NM_009762.1 (Mm); NM_198274 (Hs) 
 
       MazR/ZBP89 
Hsseq-1406 CACCCCCACCCCCAACCCCCACCAGGAAA-TAGATGCATCCCAGGACT-----AAAAATCTTACA 
           ||| | ||  |   | |  | |||| ||  || |   |  |||| | |     ||||||  ||||          
Mmseq-1006 cacactcaaactataacaac-ccag-aatctaaacata-ACCAGAAATTTAAAAaaaatactaca 
    A Mef2         MTATA  MEF2   MMef2 
 
          TATA(-)MTATA(+) 
Hsseq-1347 TGGAAGTCAAGCCAGAGCTCCAGA-TCTGCAAGT—GTATTTCTTTTAAACCTCAGTAAAAGCTGC 
             ||||  |||||| ||  | ||| || |||||    ||| |   | ||||| ||||| | | ||    
Mmseq -943 cagaagctaagccacagagc-agaatccgcaagggccattccc--tcaaccttagtaagataggc 
                cRel           LMO2COM-2 
 
     
Hsseq-1284 CTGATAGCCAAGAACAGTGGCATTTAGTTCAACGGGGATTTTAGATTCGTCTTTCCAGTGTCCTCAC   
           | | | |||||| |  ||||   | | ||| || |||||||||||  | |   || | | ||  | | 
Mmseq -881 cagttggccaagga--gtggtgctaaattc-accgggattttagaaccatgcctctaatatcgcccc 
             Maz 
 
          MTBF    Stat3     Stat3/ 
Hsseq-1217 TCCTGAGTAAGAAGAAGGACAGAGCACGTTGGTATTTTCCTGGCAGCAGACACATGTTAAAGGAAAT    
           |||||||| ||| || |||||||||| |||| || |||||||||  |||||||||  |  ||| | | 
mmseq -817 tcctgagtgagaggagggacagagcaagttgatactttcctggccacagacacatccttgagggagt 
               PBX/Meis 
    
  PBX1/BCL6,PBX/Meis/LMO2COM-2  MTBF(+)/MMEF2/TATA 
Hsseq-1150 TTGATAGAAAGATA---GAGATGGGGGTTGCTATTTTTATAGCCTGCCTTGTCTGTATCCAGCCTGC  
           ||| ||||||| |    |||| ||| | | ||  ||||  | |||||||| |||| |||||| ||| 
Mmseq -750 ttggtagaaaggtctgggagacgggtgct-cttcttttcaatcctgccttctctgaatccag-ctgt 
  BCL6          COMP-1 Stat5    MyoD 
 
         c-Rel     ZBP89 
Hsseq-1086 CTCCAGCATACCAGCATCACCAGCAGTGCTAAGAACAGGGAATTCCATGCTGTGGAGTAGGGGGTGC 
           ||      |    | ||||||||   |||| ||||    || ||||||||  ||| ||  ||| |||     
Mmseq -685 ct------t----gtatcaccagtgatgctgagaattctgacttccatgccatggggt—-gggctgc 
               Oct1 
 
        GATA    
Hsseq-1019 TGTAAGAGCCCCAGGTGATACTGGA-GAGGAAAAATGCCCCCTTGGAG-CCTAAATAGTACTGTTA 
           ||| |||| | ||| ||| |  ||| ||| || ||||  ||||| ||| ||| || ||| ||| || 
Mmseq -630 tgtgagagacacagctgacatgggaggagaaacaatg-tccctt-gagtcct-aagagttctgcta 
       AP4         Sox5 
 
                      
      Oct1                        Meis1 
Hsseq -955 CGTATAT-GCCAAGGGCTCAGTTTAGCTTCTTCTTATTATTTATTTATTTATTTATTTATTTATTTA 
           | ||| | || || |||||| |||||||||| ||  |||||| 
Mmseq -567 catatgtggcaaaaggcc tt cc aa tt tt tt tt aa gg cc tt tt cc tt gg cc tt aa tt tt tt aa tt tt tt ------------------------- 
       SRF                 MTBF 
 
Hsseq -889 TTAATTTTTTGTTGAGACGGGGTCCCACTCTGTCGCCCAGGCTGGAGTGCAATGGCGCGATCTCGGC 
Mmseq      ------------------------------------------------------------------- 
          BCL6 
Hsseq -822 TCACTGCAACCTCTGCCTCCCAGGTTCAAGCAATTCTCCTGCCTCAGCCTCCTCAGTAGCTGGGATTA 
Mmseq      -------------------------------------------------------------------- 
Hsseq -754 CAGGCGCCCGCCACCACGCCCAGCTAATTTTTGTATTTTTGGTAGAGACGGGGTTTCACCATGTTGGT 
Mmseq      -------------------------------------------------------------------- 
     Mef3 
Hsseq -686 CAGGCTGGTCTTGAACTCCTGACCTCAGATGATCCATGTGCCTCGGCCTCCCAAGGTGGGGATTACAG 
Mmseq      -------------------------------------------------------------------- 
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Hsseq -618 GCGTGAGCCACCGTGCCCAGCCCTCAGTTTAGCTTCTGCTGCTAAACAGT—-CCACCCTTGGGAGAGA 
                                 |||| |||||||||||||  | |    |  ||||     || |||| 
Mmseq -551 ----------------------cc tt cc aa tt tt tt tt aa gg cc tt tt cc tt gg cc tt aa tt tt tt aa tt tt tt CTTGCCAC-----GGGGAGA 
 
    MAZR(+)/SP1(+)       Nkx2.5(-)       Meis-1(+) 
hsseq -552 GACT--GAAAAGGGTGGGGCGAGGG-CCCATCTCACTTGAGAAAGTGCAAGCCTGACAGCTGAAGGGT 
            |||  |    ||||||||| |||| |||| |||||||||||||||      |||||||||||||||| 
mmseq -505 CACTAGGGTGGGGGTGGGGCAAGGGGCCCACCTCACTTGAGAAAGTCTGCATCTGACAGCTGAAGGGT 
                     MAZR(+)/SP1(+)       Nkx2.5(-)       Meis-1(+) 
             
               Myogenin/NF1(+)   MyoD(+)/PBX-1/Meis-1(+)/ 
hsseq -487 CCCAGAGCAGCAAATATCACCTTG-----TTTCTATGGGACCATTCCAGCTGTCTGCTTTTGATTGAC 
           ||||| ||||| | ||| || |||     ||||| |  | ||| ||||| ||||| |||||||||| | 
mmseq -437 CCCAGGGCAGCCATTATTACTTTGCCTCTTTTCTCT--GTCCACTCCAGTTGTCTCCTTTTGATTGTC 
       Hox1.3             Myf5(-)/PBX-1/Meis-1(+)/   
                     
        TGIF(+)/Comp1(+)/  MMEF2(+)        
    PBX-1(-)       MTBF(-)       
hsseq -424 AGAGGCATCTGGCTGCTAAAAATACCCTCCTGACCAAATGTTCCCTACTCCAACTAAAGCCGAACAGG 
           ||||||| ||||  |||||||||| ||| |||||||| || ||   | | || || |||| ||| | 
mmseq -371 AGAGGCACCTGGAGGCTAAAAATAGCCTACTGACCAAGTGCTCTTGATTTCATCTCAAGCTGAATATG 
        TGIF(+) /Comp1(+)/  MEF2(+)        
    PBX-1(-) LMO2COM-1     MTBF(-) 
 
hsseq -356 ATTGTTGCAGTTCAGAACTTAGCACATACAGATAGCTTCT--------GCTTGCAATGGAACCTCTCA 
           ||     ||||||||||||  ||||||| | |  ||  |||        ||| |||   | ||| ||   
mmseq -303 A---CCGCAGTTCAGAACACAGCACATGCTGGGAGTATCTTTAAGTGGGTTTTCAA---ATCCTGTC- 
    
       SRF      TCF11(+)      
hsseq -296 AAACTTTTCAGGCCCTATG------CCATATTAACCCATGGTCATTTTCTGTTCTGTCGGCTTTGCTG 
                | |||||  | |||      ||| | || |   ||||||||||||||  ||  | |||| ||| 
mmseq -242 -----TGTCAGGATCCATGTCAGGACCACACTAGCTTGTGGTCATTTTCTGTCTTGGTGTCTTTTCTG 
              TCF11(+) 
       
hsseq -234 GGTGATGAATGAAACTCTTCCCAGTTCACTTGTTCTCTTGTCTGTCCCATCCCCACCTCCAGGAAAAG 
           ||||||||| || ||  ||   ||  ||      |||||   || ||  | |   ||||| |  | || 
mmseq -179 GGTGATGAACGAGACCTTTGTAAGGCCA------CTCTTCATTGGCCTTTTC---CCTCCTGACACAG 
           Myogenin/NF1(+)   Pax1(+) 
  
             ZBP-89(-)/MAZ(+)                Pax1(-)                 TATA      
hsseq -166 TAGCAGAGGGGGAGGTGAGGGCCCAGTAGCTGAGAGCGAGTAGGGAAGGGGAGGTGGCTTGTCCATTTA 
           | |  |||||||||||||||||||||     ||||| |||| ||||||||||||||||  ||||||||| 
mmseq -120 TGGTGGAGGGGGAGGTGAGGGCCCAGCTCTGGAGAG-GAGTTGGGAAGGGGAGGTGGCCAGTCCATTTA 
            ZBP-89(-)/MAZ(+)           TATA 
         MTBF(-) 
hsseq  -97 TAGTCTTGCTCTTTGGGATGCTGAAGGTGCTGAAATAGCA---ATGACAAGAGACTTGGCTCAGTGTTA 
           ||||| |||||||||||| | |||||| ||| | ||||||   | | ||| || |||||||||| |  | 
mmseq  -52 TAGTCCTGCTCTTTGGGACGATGAAGGAGCTAA-ATAGCAGCAAGGACAAGAGGCTTGGCTCAGTGTGA 
         MTBF(-)         +1 
 
        +1     Sox9(+)   
Hsseq   -31 AATAACTGCCGCGCTGGCCTGACAGTCTCTGAGATGACAATAGGGAGAATG 
               | |  || ||  |||||||||| |||||||||||||||||| || ||| 
mmseq   +17 GCGAGCCACCTCGAAGGCCTGACAGACTCTGAGATGACAATAGGCAGCATG 
          Pax8(-)              Sox9(+)   
Fig 3.1  Regulation of Smyd1 must be highly conserved as the non-coding regulatory 
region has been conserved in mammalian evolution.  Matching base pairs are 
indicated by a |, mismatches are signified with a space, and putative binding sites are 
annotated in matching text.  Regions in bold are the most highly conserved at the 
sequence level.
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Homology in non-coding sequences between mouse and human: region 1 
When extending the 600bp region to 1kb for analysis, there is added DNA 
homology after an approximately 300 bp insert into the human sequence.  This region in 
both species encodes many of the same putative transcription factor binding sites.  
However, these are not conserved at the level of DNA sequence or proximity to the 
coding start site.  These putative sites include Srf, Myogenin, Oct1, and Bcl6.  There are 
also duplicates of the following TATA, Pbx/Meis, Maz, and MTBF. 
 
SRF: Serum Response Factor 
Srf is an ancient transcriptional activator with a MADS DNA interacting domain.  
Srf is thought to be a scaffolding platform that mediates expression of entire gene 
programs and heightened expression coincides with striation of skeletal and 
cardiac muscle [57]. 
     
Myogenin 
Myogenin, or MyoG, is a MRF, which are thought to be “master regulators” of the 




Oct1 is an ubiquitously expressed transcription factor and has a general affect on 




Bcl6 is most highly studied in B-cells and T-cells, but is moderately expressed in 
most tissues.  Bcl6 is a known transcriptional repressor [59]. 
 
Extending sequence analysis to approximately 3kb upstream of Smyd1 in mouse and 
human genomes leads to very little DNA homology that is not already mentioned. 
 
Homology with other skeletal and cardiac muscle promoters 
Because there were so many interesting putative sites, I attempted to narrow down 
candidates by extending the analysis to include other genes with similar expression 
patterns.  Desmin is an intermediate filament that is expressed in both the heart and 
skeletal muscle [60].  Hop, on the other hand, is expressed only in the heart [61].  
Comparing potential binding sites from mmSmyd1, hsSMYD1 and mmDesmin putative 
regulatory sequences yields four conserved binding site clusters.  While the same factors 
are present in the putative Hop regulatory region, they are not clustered in the same 
subgroups, suggesting that this pattern is important for skeletal muscle specific 
expression, but not for cardiac specific expression (Fig 3.2).   
The second, and most interesting, cluster contains Sp1/GC box elements, MazR, 
Meis1, Mef 2 and MyoD or Myf5 binding sites.  This cluster is very likely essential for 
skeletal muscle expression.  Although the Pbx binding site does not register on the 4 
sequence analysis, both putative Smyd1 promoters contain both Meis1 and Pbx adjacent 
to the MRF site, MyoD or Myf5.   As mentioned above, PBX/Meis1 heterodimers bind 
cooperatively with MRF heterodimers.   Although the particular MRF is not identical in 
all four promoters, the varying binding proteins, Myf5 and MyoD, are thought to have 
overlapping functions [62].  Mef2 is also an important transcriptional activator for the 
myogenic program.  While the SP1 and Maz elements are not accompanied with a Zbp-89 
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site, they are represented in three promoters with similar expression, suggesting that they 
play a role independent of Zbp-89.   
The first observed cluster includes a TATA box and an MTBF binding site.  
Although this TATA box is not located near the canonical position, -25, it is possible that 
the true or alternative transcription start site has not yet been identified.  The third cluster 
contains Stat and Maz and the fourth cluster contains, Evi1, TATA, and Stat. 
 
Stat: Signal Transducers and Activators of Transcription 
Seven members of the Stat family have been identified in both the human and the 
mouse genome.  Stat family members can receive a signal at the cell membrane 
and activate transcription without the use of intermediate players.  They are often 
regulated by phosphorylation [63].   
 
Evi1: Ectopic Viral Integration Site-1 
Evi1 was first described in Leukemia studies.  Viral integrants into the host 
genome induced activation of Evi1, which caused leukemia.  While Evi1 is 
minimally or unexpressed in neonatal or adult skeletal muscle, it is expressed 
ubiquitously at embryonic day 9.5 and is present in the developing limb bud and 
heart.  Evi1 binds DNA in a sequence specific manner and can activate 
transcription through several zinc finger domains.  Evi1 associates with co-
activators and co-repressors [64]. 
 
Based upon the above analysis, I created constructs that used 3kb, 1kb, and 0.5kb directly 
upstream of the transcription initiation and cloned these putative regulatory domains into 
a vector that contained a promoterless AUG-β-gal.  The 1kb and 3kb constructs were 
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used to create transgenic mice.  While 1kb is sufficient to drive expression of Smyd1 in a 
semi-endogenous manner, the 3kb construct gave the same pattern, albeit stronger LacZ 
expression.  Transgenic mice created from either construct failed to express the reporter 
in the left ventricle (Fig. 3.3).  This aberrant expression is not unusual in transgenic 
reporters.  Like Smyd1, many other genes are endogenously expressed in both the left and 
right ventricles but transgenic attempts to fuse large segments of the promoter to a LacZ 
reporter have failed to produce expression in the left ventricle.  However, directed 
recombination of lacZ into the endogenous site of these genes does express the reporter 
equally in both chambers, suggesting that there is a yet unknown, but non-unique element 
in left ventricle expression of many cardiac genes, including Hop [61], Mlc2v [23] and 
Nkx2.5 [65].   
I also created mutants in the proximal and distal Mef2 sites, the Myf5 and MyoD 
sites (Fig. 3.4), although these constructs were never used to create transgenic mice or 
analyze the effects of the mutated sites on transcription.  Meanwhile, collaborators in Eric 
Olsen’s lab at UT Southwestern established similar transgenics using a vector that 
contained hsp68-LacZ, which provides a basal promoter fused to the reporter gene (Fig. 
3.5).  These transgenic mice expressed LacZ in the same pattern as those with simply the 
initiation codon, but at a much higher level (Fig. 3.6).  This set of constructs also 
displayed higher expression when 3kb of regulatory region was fused to the basal 
promoter, but 0.6kb was sufficient for expression (Fig. 3.7).   
Because Mef2c is known to play a definitive role in both cardiac and skeletal 
muscle myogenic program and conserved putative binding sites were present, we 
hypothesized that Mef2c binds directly to the Smyd1 promoter in order to act as a 
transcription factor.  In fact, when electromobility shift assays were done with MEF2c 
protein on the wildtype construct, we detected a supershift, which supports this 
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hypothesis (Fig. 3.8A).  A mutation was made in the putative Mef2 site on the hsp-90 
basal promoter background and this construct was negative for Mef2c binding (Fig. 
3.8B).  Mutating the Mef2 site also ablated expression in the cardiac tissue when 
transgenics were created, but skeletal muscle expression was intact (Fig 3.8C).   
From sequence analysis, I predicted that this Mef2 site is important in skeletal 
muscle expression due to motif conservation with mouse and human Smyd1 muscle 
regulatory factors as well as that with Desmin.  However, there is a second, more distal 
Mef2 site in the mouse putative promoter that may compensate for the lack of the mutated 
Mef2 site.   While 0.6kb of the promoter is sufficient for driving expression, expression is 
heightened when 1kb, which includes the distal Mef2 site, is available.  I predict that the 
distal Mef2 site is important for skeletal muscle expression in the endogenous context.  In 
fact, a Mef2c conditional knockout was recently published from which it was shown that 
Smyd1 is knocked down two-fold in the skeletal muscle of a MyoG-Cre induced Mef2c 
knockout [66].    
We also made mutations of 3 E-boxes, DNA motifs known to bind to MRF hetero 
and homodimers, in the background of the 600bp-hsp90 construct.  Only one of these E-
boxes was recognized in the genomatix computational approach as a MRF binding site, 
MyoD.  While all three core E-box sequences are present, only one of the E-boxes is 
recognizable as an MRF binding site by genomatix software.  Because single mutations 
were not created, we cannot predict the role of each individual E-box sites.  When all 
three E-box sequences are mutated, cardiac expression of the reporter is maintained, but 
skeletal muscle expression is lost in the context of the 600bp-hsp90 basal promoter 
construct (Fig. 3.9).   
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Fig 3.2  Several Motifs are conserved beteween mmSmyd1, hsSMYD1, and 
mmDesmin, but not with mmHop.  There are many putative transcription factor binding 
sites in common between all four promoters.  However, the heart only promoter of 
mmHop does not conserve the same organization as the cardiac and skeletal muscle 
expressing promoters of mmSmyd1, hsSMYD1, and mmDesmin.  There are four clusters, 
indicated in brackets, in common between these 3 promoters.  The most impressive of 




Fig 3.3  Time progression of reporter expression of a 1kb regulatory region directly 
upstream of Smyd1.  A Smyd1 reporter is expressed as early as E8.5 in the right heart 
and E9.5 in somites.  Expression is heightened and maintained throughout development.  
The top panel represents whole embryo staining at the respective ages.  The bottom panel 




Fig 3.4  Promoter Reporter Constructs in the Promoterless AUG Background.  7 
wildtype and mutagenic constructs were created on the promoterless background.  
Interesting putative transcription factor binding sites are annotated on the 1kb wild type 
construct and represented by hash marks on all others.  Mutations are described on the 
left and marked with an X on the promoter.  The 1kb wildtype and 3.5kb wildtype 





Fig 3.5  Promoter Reporter Constructs Fused to a Basal Heat Shock Promoter. 
Regions of 5' flanking DNA immediately upstream of Smyd1 exon 1b used to create lacZ 
transgenes are shown. Nucleotides are numbered relative to the transcriptional start site, 
which is designated `0'. Construct number is indicated on the left, and the corresponding 
expression pattern is summarized on the right. All constructs, except construct 4, contain 
the indicated upstream genomic regions fused to the hsp68 basal promoter and the lacZ 
gene. Construct 4 contains the region from –986 to +75 bp fused directly to promoterless 
lacZ. The Mef2 site was mutated in constructs 5 and 6, and the three E-boxes were 
mutated in construct 7. Asterisk denotes constructs that were also used to generate stable 
transgenic lines. The numbers of F0 transgenic embryos compared with the total number 
of transgene-positive embryos are shown.  Figure extracted from Phan and Rasmussen, et 
al [67]. 
 38
Fig 3.6  Expression in 
the 1kb promoterless 
constructs is much 
weaker than expression 
in the 700 bp hsp90 
promoter constructs. 
Expression patterns of 
transgenes directed by –
637/+196 and –986/+75 
regulatory regions of 
Smyd1 at different 
developmental stages. (A-
H) Transgenic embryos of 
the indicated ages from a 
stable transgenic line 
harboring construct 2 (–
637/+196; see Fig 3.5). 
(A-D,G,H) Frontal views; 
(E) right-side view; (F) 
transverse section. Two 
independent stable 
transgenic lines displayed 
identical patterns of lacZ expression. (I-P) Transgenic embryos of the indicated ages from 
a stable transgenic line harboring construct 4 (–986/+75; see Fig 3.5). (J,K) Enlarged 
regions of the embryo shown in I. (M,N) Transverse sections at different levels of the 
embryo shown in L. (P) Transverse section of the embryo shown in O. rv, right ventricle; 
lv, left ventricle; oft, outflow tract; vc, common ventricular chamber; m, myotome.  
Figure extracted from Phan and Rasmussen, et al [67]. 
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 Fig 3.7  Expression patterns of 
transgenes directed by distal (–
3303/+196) and proximal (–637/+196) 
regulatory regions of Smyd1 at E11.5. 
Whole-mount views of F0 transgenic 
embryos at E11.5 with construct 1 (–
3304/+196; A-D) and construct 2 (–
637/+196; E-H) are shown (see constructs 
in Fig 3.5). (A,B,E,F) Left and right sides 
of embryos are shown. (C,D,G,H) 
Histological sections. (C,D) Robust 
expression of construct 1 is seen in the 
ventricular and atrial chambers of the heart 
and somite myotomes. Identical expression 
patterns were seen in 6 out of 7 embryos 
with this construct (data not shown). (G,H) 
Construct 2 is expressed specifically in the 
right ventricular chamber and somite 
myotomes. Identical expression patterns 
were seen in 5 out of 5 embryos with this 
construct (data not shown). m, myotomes; 
oft, outflow tract; ra, right atrium; rv, right 
ventricle; lv, left ventricle; la, left atrium.  
Figure extracted from Phan and 
Rasmussen, et al [67]. 
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 Fig 3.8  A Mef2-
binding site is required 
for cardiac expression 
of Smyd1. (A) The 
sequence of the mouse 
Smyd1 gene containing 
the essential Mef2 site 
and the E-boxes is 
shown along with 
homology to the 
corresponding regions 
from other species. (B) 
5' flanking sequences of 
mouse Smyd1 genes 
showing conserved 
Mef2 site at –329/-320. 
(C) A gel mobility shift 
assay was performed 
using nuclear extracts 
from COS-1 cells 
transfected with a MYC-Mef2C expression plasmid and the radiolabeled Mef2 site shown 
in panel A as probe. Specific and nonspecific competitors were used at 50-fold molar 
excess. Antibody supershift used 1 µg of polyclonal anti-MYC antibody. (D,E) Mef2 site 
is essential for Smyd1 expression in the anterior heart field in vivo. F0 transgenic mouse 
embryos were generated using constructs 1, 2, 5 and 6 (see Fig 3.5), and stained for 
expression of ß-galactosidase at E11.5. Mutation of the Mef2 site abolished expression in 
the anterior heart field without affecting expression in skeletal muscle. Four independent 
F0 transgenic embryos were analyzed with construct 5 (D) and five independent embryos 
were analyzed for construct 6 (E). All embryos with each transgene showed comparable 
expression patterns.  Figure extracted from Phan and Rasmussen, et al [67]. 
 41
 
Fig 3.9  E-boxes are required for Smyd1 expression in developing skeletal muscle. 
Mutation of the three E-boxes in the Smyd1 upstream region (construct 7 in Fig 3.5) 
caused a loss of skeletal muscle expression without affecting expression in the heart, as 
seen in a whole-mount lateral view (A,B) and transverse sections (C) of five independent 
F0 transgenic embryos at E11.5. a, atrium; rv, right ventricle; lv, left ventricle; oft, 
outflow tract.  Figure extracted from Phan and Rasmussen, et al [67].
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Discussion 
Conservation of DNA sequences between species is typically indicative of an 
essential function by those sequences.  Typically this function is to code RNA or protein, 
however, when non-coding DNA is conserved it suggests that there are important DNA 
binding sites within the conserved regions.  However, because there is not much variation 
at the DNA level, many putative binding sequences may also be conserved between 
species regardless of whether the site is a true in vivo target site.  Therefore, common 
putative sites in non-conserved regions may be equally important—they are still 
conserved although the DNA sequence is not. 
Predictions have been made based on computational analysis and further validated 
via literature reviews and some experimentation.  I have found four clusters of putative 
binding sites that are likely important for normal expression in skeletal muscle based on 
the regulatory regions of multiple genes that produce skeletal muscle and heart specific 
expression.  These predictions have not been tested experimentally, however, this could 
be done given the time and money to create more mutated promoter-reporter mice.  The 
most impressive of the four clusters contains a Pbx-1, Meis-1 and MRF binding site, 
Mef2, and Sp1/Maz sites.  Pbx and Meis are known to bind as heterodimers cooperatively 
with all MRF heterodimers.  Mef2 is known for a large role in skeletal and cardiac muscle 
and we have shown this site to be essential for cardiac expression.  Sp1 and Maz are 
known to repress and activate in different contexts.  This cluster of sites is not only 
conserved between mouse Smyd1, human SMYD1, and mouse Desmin, it is also in 
precisely the same location in mouse and human SMYD1 regulatory regions.  The second 
cluster is much smaller, but is also in the same location in both mouse and human 
regulatory regions and contains a TATA box adjacent to an unknown myotube specific 
enhancer.  The third and fourth clusters are combined in mouse and human SMYD1 
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regulatory sequences and contain several Evi1 sites, a TATA box, Maz, and Stat.  While 
these are not spatially conserved, the mouse regulatory region does contain two Lmo2 
comples half sites that would allow the promoter to fold [68] and bring the mouse region 
approximately as close to the initiation site as the human region (Fig 3.10).  While it is 
unlikely that the TATA box has any significance at this location, it does tend to cluster 
with the Evi1 and Stat putative transcription factor binding sites. 
Predictions specific to Smyd1 regulatory regions have been made by comparing 
putative sites in mouse and human promoters.  Some factors, like Bcl6, have been 
included despite seeming unlikely candidates in controlling the spatial expression of 
Smyd1.  There was no evidence to exclude these factors and doing so would be arbitrary 
manipulation of data.  However, by taking the factors we have shown to have importance 
and those that are likely to be important, I have created a schematic of the most likely 
players in the transcriptional regulation of Smyd1 (Fig 3.10).  This includes, a TATA box 
and Myotube specific enhancer, Myogenin, 2 Mef2 sites, two Lmo2 complex half-sites, 
Myf5, PBx/Meis1, Meis1, Sp1/Maz, Comp1, and MyoD.   
 It would make sense that Myogenin, Myf5, and MyoD are all involved in Smyd1 
transcription because these are three of the four MRFs and Smyd1 expression is 
maintained in all known skeletal muscle in all known stages of development and 
adulthood.  Therefore at different times and places, different MRFs may be necessary to 
activate Smyd1 expression.  By mutating three putative E-boxes, which coincide with the 
putative Myf5 site, the putative Lmo2 complex half site 1, and an unidentified region 
regulatory region, we have shown that skeletal muscle transcription is dependent on E-
boxes and likely MRF heterodimer binding.  Skeletal muscle transcription may also be 
dependent on the folding induced by the Lmo2 complex which would position the distal 
Mef2 site.  We have shown that the proximal Mef2 site is only essential for cardiac 
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expression, but we know that skeletal muscle Mef2c knockouts cause a two-fold 
reduction of Smyd1.  Therefore it is likely that the distal Mef2 site affects, but is not 
essential for Smyd1 expression.  The Mef2 mutations analyzed were either on the 0.6kb 
regulatory context and the E-box mutations affected the integrity of the Lmo2 complex 
half site, which contain and are dependent on E-boxes.  Comp-1 is also known to enhance 




Fig 3.10  A comprehensive prediction of important mmSmyd1 promoter binding 
sites.  Based on experimentation we have shown that the Mef2 site at -360 as well as the 
3 E-boxes that overlap the putative Myf5, LMO2 complex half-site 1, and an unidentified 
putative binding site are essential for proper transcription in several settings.  The other 
putative binding sites are expected after extensive computational analysis of the sequence 
and literature reviews.  Mutations analyzed are indicated with an *.  The position is 
marked relative to the +1 transcription site.  (+) and (–) indicate whether the putative site 
is on the coding or non-coding strand.   
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Chapter 4.  Smyd1 is Essential in all Stages of Embryonic Cardiac Development. 
 
Targeting vectors made for eukaryotic knock-ins or knock-outs typically include 
an antibiotic cassette, Neomycin, which allows for positive selection.  However, this 
screening strategy integrates a Neomycin cassette into the gene locus.  Some reports 
indicate that neomycin can provide splice acceptor and donor sites in order to incorporate 
itself into the mRNA, creating a hypomorphic gene product [69, 70].  Theoretically, the 
presence of the Neomycin cassette could also displace essential regulatory regions and 
affect regulation or expression of genes near the locus.   
With the introduction of Cre/LoxP and FLP/FRT technology, it has become 
possible to remove the drug resistance cassettes after integration of the targeted vector 
into the mouse genome.  Cre recombinase is a protein isolated from bacteriophage P1 
that has been shown to specifically recognize a LoxP site, a 34 bp sequence, and induce 
recombination between any two LoxP sites [71].  If the LoxP sites are on the same 
chromosome or plasmid in opposite orientations, Cre recombinase causes an inversion.   
However, if the LoxP sites are in the same orientation on the same chromosome or 
plasmid, Cre recombinase excises all DNA between the two sites [72].  Similarly FLP 
recombinase, first identified in yeast, specifically recognizes and induces recombination 
of FRT sites, a distinct DNA sequence [73].   
It has also become possible to use these same sites to knock out endogenous DNA 
sequences of interest conditionally, or only in specific tissues, cell lineages, or stages of 
life, by using transgenically expressed recombinases under the control of specific 
temporally and/or spatially regulated promoters.  Segments of interesting DNA, usually 
encoding specific genes of interest, are flanked by either LoxP or FRT sites and 
introduced into the mouse genome via targeted knock-in technology.  Mice with the 
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targeted knock-ins of LoxP or FRT sites are mated with those that carry a transgenic 
allele of the appropriate recombinase, which are fused to a known promoter in order to 
induce specific, predictable patterns of expression.  Thus, the recombination event occurs 
at the genomic level only in the appropriate temporal and spatial manner.  In many recent 
conditional knockouts both recombinases are employed.  Often the FRT/FLP system is 
employed to specifically remove the Neomycin cassette and the LoxP/Cre system is used 
to induce the knockout of the gene of interest.  Because FLP/FRT tools were not well 
developed when we initiated cloning for the mouse Smyd1 conditional knockout, we 
created a targeting vector in which both a region of the Smyd1 gene as well as the 
Neomycin cassette were flanked with LoxP sites. 
The conventional Smyd1 mouse knockout (Smyd1KO/KO) yielded a very interesting 
early embryonic cardiac phenotype.  In the Smyd1 null embryos, there was an expansion 
of “cardiac jelly”, excess hyaluronic acid within the chambers, a pericardial edema and 
lack of ventricular septation [10].  The single ventricular chamber had the molecular 
markers of a left ventricle, but lacked markers of right ventricles [10].  However, because 
Smyd1KO/KO was embryonically lethal, these mice did not allow us to examine the role of 
Smyd1 in other temporal and spatial specific contexts and prevented us from collecting 
large amounts of Smyd1 deficient tissue for molecular analysis.  Also, we could not prove 
that the phenotype observed in the conventional knockout was due to an absence of 
Smyd1 in any particular tissue.  The phenotype could have been due to non-autonomous 
effects on the heart or effects caused by the introduction of the neomycin cassette to the 
locus instead of the absence of Smyd1 gene products specifically in the heart.  Therefore, 
we further investigated the role of Smyd1 in vivo by creating Smyd1 conditional knockout 
mice. 
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As discussed in chapter 1.1, the Smyd1 gene expresses multiple alternatively 
spliced isoforms and the initiation site varies for different isoforms.  Therefore, similar to 
the conventional Smyd1 knockout, we opted to target exons that were common in all 
known isoforms.  We created a targeted knock-in line of mice that had LoxP sites 
flanking Smyd1 exons 2 and 3 followed by a Neomycin cassette and a third LoxP site 
(Fig. 4.1A).    This was electroporated into 129S6 ES cells and selected for with G418 
and gancyclovir.  Clones were screened for homologous recombination by Southern 
blotting (Fig. 4.1B).  Correctly targeted ES clones were injected into C57BL/6 
blastocysts to create 129.Bl6 chimeric mice, which were mated with C57BL/6 females to 
create germline knock-in mice.  We then obtained existing Cre mice from various labs in 
order to further study Smyd1 in cardiac and other tissues.   
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Fig 4.1  Targeting strategy of Smyd1 Flox allele.  A.  The targeting vector (II) was 
electroporated into SM1 (129S6) ES cells.  After selection with G418 and gancyclovir, 
surviving clones were screened for homologous recombination with the genomic locus 
(I).  The resulting targeted knock-in (III) was identified by southern blot.  ES cells 
showing correct integration in both arms were injected into C57Bl/6 blastocysts, which 
were then transferred into the uteri of 2.5 d.p.c. pseudo-pregnant females to create 
chimeric mice.  The chimeric mice were mated to C57Bl/6 females to create a germline 
knock-in.  The germline mice were crossed to a ubiquitous expressing EIIA-cre mouse 
and progeny were screened for the neo deletion (IV) by southern blotting.  B.  Southern 
blot of ES cells.  Genomic DNA was digested by BglII and SalI and probed with pr3 to 
distinguish the 13.7kb wild type allele from the 7.0 kb targeted allele.  Wildtype 129 
DNA as well as the Targeting Vector were included as controls.  Data not shown:  
Genomic DNA was digested by BglII and SalI and probed with pr2 to distinguish a 
13.7kb wild type allele and a 4.5kb targeted allele. Controls were included. 
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4.1  The EIIA-Cre induced Smyd1 knockout recapitulates the conventional Smyd1 
KO. 
In order to determine that the phenotype derived from the conventional mouse 
knock-out, Smyd1KO/KO, was due to the absence of Smyd1 gene products and not to the 
introduction of the neomycin cassette, we recreated the Smyd1 knockout using EIIA-cre 
transgenic mice.  This mouse line was a C57Bl6/FVB hybrid created in the Westphal lab.  
EIIA-cre is expressed in pre-implantation zygotes [74].  Therefore, EIIA-cre induces 
recombination during the single cell stage of embryogenesis and all cells in any particular 
embryo should contain a genome that reflects the same recombination event:  a 
ubiquitous effect.   
When mating EIIA-Cre (Bl6.FVB) mice to the original Smyd1KI/+ mice (Bl6.129) 
several recombination events can occur on the Smyd1KI allele, including no deletion 
(Smyd1KI), total deletion (Smyd1ΔKI), deletion of only the neomycin cassette (Smyd1Flox), 
and deletion of the endogenous sequence, but not neomycin (Smyd1~KO) (Fig 4.2).  
Resulting genotypes were screened via Southern blotting (Fig 4.1).  Smyd1Flox mice, 
BL6.FVB.129 hybrids, were backcrossed one generation to C57BL/6J mice and screened 
for the absence of Cre and presence of Smyd1Flox.  These were kept for breeding to tissue 
specific Cre lineages.  Smyd1ΔKI were bred to homozygosity to compare to the original 
Smyd1KO/KO mice. 
The Smyd1ΔKI allele varies from the Smyd1KO allele in two ways.  Firstly, 
Smyd1ΔKI does not contain a neomycin cassette while Smyd1KO does.  Secondly, Smyd1KO 
deletes an extra 290 base pairs in the intron between exons 3 and 4.  The time of death 
and the gross phenotype of Smyd1ΔKI/ΔKI match that of Smyd1KO/KO (Fig 4.3), suggesting 
that the addition of the neomycin cassette and the varying intron segment plays no role in 
this phenotype.  Therefore this eliminates the possibility that the Smyd1 conventional 
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knockout phenotype is caused by a neomycin hypomorph and supports the hypothesis 




Fig 4.2  Possible LoxP recombination events.  LoxP sites are designated as A, B and C.  
Recombination events can occur between A and B resulting in Smyd1Flox, B and C 
resulting in Smyd1~KO, A and C resulting in Smyd1ΔKI, or not at all maintaining Smyd1KI.  
Results of these are depicted above. 
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Fig 4.3  Smyd1ΔKI/ΔKI phenocopies Smyd1KO/KO.  Mice that screened positive for the 
Smyd1ΔKI allele were timed mated to each other and their embryonic, homozygous 
offspring were analyzed for gross phenotype.  The time of death and outward appearance 
match that of the conventional Smyd1 knockout suggesting that the Neomycin cassette 
does not contribute to this phenotype. 
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4.2 The Nkx2.5-Cre mediated Smyd1 knockout demonstrates that Smyd1 is 
essential post ventricular septation. 
Nkx2.5-Cre mice were obtained from the Olson laboratory on the B6C3F1 strain, 
which is an isogenic, first generation hybrid of C3H and C57Bl/6J.  Recombination 
induced by Nkx2.5-Cre occurs as early as E8.0, during the linear heart-tube stage of 
cardiogenesis, and is confined to the cardiac ventricles at E8.5 with minimal 
recombination in the outflow tract and atria at E12.5 [75].  By crossing the Smyd1Flox 
allele to the Nkx2.5-Cre transgene, we analyzed whether the Smyd1 deficient phenotype 
is due to an absence of Smyd1 in cardiac ventricles.   
Because mice rarely show phenotypes due to heterozygosity or partial deletion, 
because we were not sure how effective Cre recombination would be, and because we 
had the Smyd1KO mice readily available, we induced our knockout on a mixed 
background: Smyd1Flox/KO.  Mice were mated in order to ultimately create 
Smyd1Flox/KO;Nkx2.5-Cre+/? mice (BL6.FVB.129.C3H) as well as the following breeders 
of the same background: Smyd1Flox/WT; Nkx2.5-Cre+/? and Smyd1KO/WT; Nkx2.5-Cre+/?.  
Once this combination of alleles was obtained, these mice were only crossed to each 
other, thereby maintaining a population that is similar and inbred, but non-isogenic. 
 
Tissue Surveys on the Smyd1 Locus 
In order to confirm that the Nkx2.5-Cre+/? transgene is effective on the Smyd1Flox 
locus as previously described on other loci,  DNA recombination tissue surveys were 
conducted on heterozygous Smyd1Flox/WT; Nkx2.5-Cre+/? mice.  At the time of sacrifice, I 
collected several tissues and two PCR based recombination assays were used.  The first 
assay detects Smyd1WT and Smyd1Flox alleles that have been unaltered by recombination.  
Smyd1WT does not contain LoxP sites; therefore, regardless of Cre expression, levels of 
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genomic Smyd1WT cannot decrease, providing an internal positive control.  Therefore, 
despite variance in DNA preparations from sample to sample, the Smyd1WT band 
represents 100% of one allele.  Smyd1Flox, however, is the target of recombination.  In a 
perfect system, tissues in which recombination occurs should not yield a Smyd1Flox band.  
However, most Cre recombination is not 100% effective and, therefore, we expected to 
see the band diminish or disappear in tissues displaying strong to complete 
recombination.  These PCR assays were not confirmed to be in the linear range; and 
therefore we can not quantitate the products via densitometry, but by comparing the 
Smyd1WT and Smyd1Flox bands, we can qualitate the efficiency of recombination.   
In order to test this, I performed controls on both plasmid and genomic tail DNA.  
A plasmid containing an XbaI fragment from a BAC-clone served as a wildtype plasmid 
template, while the targeting vector, pKI, used to make the conditional knockout served 
as Flox plasmid template.  By combining these two plasmids in known molar ratios, I 
assessed how well the ratio of PCR products represents the ratio of the two alleles.  The 
Flox and WT bands appear to be equal when the WT allele is 13 fold more concentrated 
than the Flox allele (Fig 4.4A).  This data suggests that the PCR reaction favors the Flox 
product.  It is not unusual for PCR reactions to prime products at different rates, although 
it is unusual for the reaction to favor the larger product.  The 30:1 WT/Flox molar ratio 
detected an obvious decrease in the Flox product.   
To determine if this favoritism also occurs in genomic DNA, I obtained genomic 
tail DNA that was determined to be homozygous for either the WT or the Flox allele.  By 
combining these two genomes in known mass ratios, I assessed whether the findings for 
plasmid DNA are true for genomic DNA.  In the genomic setting, it appears that the 5:3 
WT:Flox ratio gives equal products (Fig 4.4B).  Therefore the favoritism towards the 
Flox allele is still present, although it does not appear as severe with genomic templates.  
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A decrease in the Flox band appears in the sample with 5:2 WT/Flox ratio, which 
simulates 60% recombination.  The Flox band disappears at the 100:1 WT/Flox ratio, 
which simulates a 99% recombination.   
Tissue surveys were done on entire tissues.  However, Nkx2.5-Cre induces 
recombination primarily in the ventricles.  Although atria and valves are much smaller 
than ventricles, DNA from this unaffected tissue can still mask recombination in affected 
tissue.  There is also a possibility of contaminating tissues with red blood cells, fur, or 
other surrounding tissues.  Due to these factors, recombination is difficult to detect with 
this assay and a decrease in the Smyd1Flox band compared to the Smyd1WT band will only 
be detectable if recombination is strong.  Therefore, recombination was also assayed via 
the Floxdel assay, which detects only a recombination product.  By coupling data sets 
from both reactions I can semi-quantitatively analyze whether recombination is occurring 
in predicted patterns and whether this recombination is strong. 
PCR products from the Floxdel assay on tissues harvested from mice carrying the 
Nkx2.5-Cre transgene only occurred in heart tissue and in mice that also had the targeted 
Smyd1Flox allele (Fig 4.4C).   However, the Flox/WT PCR results did not consistently 
display a decrease in the Smyd1Flox allele compared to the Smyd1WT allele.   In Mouse #7, 
there is an obvious reduction in the Smyd1Flox allele compared to the Smyd1WT allele.  
This reduction is not obvious in surveys from mouse #4.  Therefore, while recombination 
is occurring in the appropriate tissue, it is not complete and it is possible that the rate of 
recombination varies from individual to individual.  RT-PCR confirms that expression of 
Smyd1 transcripts is reduced but not complete (Fig 4.5A) and real time PCR shows a 90% 
knockdown (Fig. 4.6B). 
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Fig 4.4  Nkx2.5-Cre Mediated Recombination of Smyd1Flox allele is detected only in 
the heart.  A) Combining a WT and Flox plasmid in known ratios displays that PCR 
favors the Flox plasmid.  However, a decrease in the Flox band is detectable when the 
WT band is significantly more prevalent than the Flox band.  B) PCR reactions also favor 
the flox product when genomic DNA is combined in known ratios.  A flox band that is 
weaker than the WT band signifies that the WT band is significantly more prevelant than 
the Flox band.  C) Analysis of Mouse tissues does not commonly detect a decrease in the 
Flox band due to recombination.  The recombination assay detects cardiac specific 
recombination, as predicted.  While the Flox/WT bands do not consistently represent an 
expected effect on the Flox allele, they do provide a positive control for all samples are 
confirm that PCR grade DNA is present in relatively equal amounts in samples from all 
tissues. 
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Fig 4.5  When Smyd1Flox is 
combined with Nkx2.5-Cre, 
Smyd1 is effectively knocked 
down and mice display an 
embryonically lethal cardiac 
phenotype.  A) A Smyd1 knock-
down is detectable, although 
incomplete at E10.5 as detected by 
RT-PCR.  B) To investigate the 
lethality, Smyd1WT/Flox; Nkx2.5-Cre 
were crossed with Smyd1WT/KO; 
Nkx2.5-Cre.  Smyd1WT/WT ; Nkx2.5-
Cre is referred to as WT and 
Smyd1Flox/KO; Nkx2.5-Cre is 
referred to as MT.  Both 
Smyd1KO/WT and Smyd1Flox/WT with 
the Cre are referred to as HET.  
Analysis of timed matings 
determines that CKO mice are 
present and normal in Mendelian 
ratios at E9.5.  Early abnormalities are detectable at E10.5 and all CKO mice are dead by 
E12.5.  Numbers shown are observed animals and numbers in parenthesis indicate 
phenotypic or dead embryos.  C) H&E stained transverse sections show pericardial 
edema, cardiac hemorrhaging, a thinned pericardium, decreased trabeculation, and poor 
septation.
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Phenotype of Nkx2.5-Cre mediated Smyd1 CKOs 
Despite the incomplete effect of the Nkx2.5-Cre on the Smyd1 locus, this 
conditional knockout, or knockdown, did prove to be embryonic lethal.  The first 50 pups 
born from matings described above yielded 20% Smyd1 wildtype homozygotes, 80% 
Smyd1 heterozygotes, and 0% genotypic Smyd1 nulls (table 4.1).  Expected Mendelian 
ratios are 25%, 50%, and 25%, respectively.  The large number of heterozygotes may 
indicate that there is selective segregation of the mutant alleles.  However, this was not 
analyzed as the more interesting feature is that homozygous mutants did not exist at 
weaning.  There was no consistent or significant reduction in litter sizes between birth 
and weaning, the age at which we performed genotyping.   
To determine the time of death of homozygous Smyd1 mutants, we analyzed 
embryos from timed matings.  At E9.0, when the conventional Smyd1 nulls are visibly 
affected, Smyd1 CKO embryos appeared to be normal.  We determined that the time of 
death varied, but was typically between E10.5 and E12.5 (Fig. 4.5B).  At E10.5 
Mendelian ratios were not abnormal and only 1 of 12 conditional knockout embryos 
displayed a phenotype.  By E11.5 Mendelian ratios were significantly lower than 
expected (p<0.01) and 60% of observed CKO embryos displayed a marked phenotype.  
100% of CKO embryos analyzed between E12.5 and E15.5 lacked a functional heart (no 
heart beat).  Although the Mendelian ratios did not continue to decrease between E11.5 
and E15.5, all observed embryos were developmentally stunted at E12.5 and no survivors 
were found at birth.  
Embryos were analyzed for phenotype at E11.5.  At this age, embryos display 
pericardial edema, cardiac hemorrhaging, poor trabeculation, disorganized ventricular 
septum, and a thinned ventricular wall (Fig. 4.5C).  Despite the fact that Nkx2.5-Cre 
induced recombination is reported to occur by E8.0, Nkx2.5-Cre induced Smyd1 CKOs 
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survive 2 days longer than the Smyd1 conventional knockouts.  This is not surprising 
because 10% of the normal levels of Smyd1 transcripts exist in the Smyd1 CKO (Fig. 
4.6B) as opposed to 0% in the Smyd1 KO.  However, it is still possible that Smyd1 is 
involved in molecular events prior to Nkx2.5-Cre mediated deletion and that the full 
expression and function of Smyd1 prior to E8.0 partially rescues the phenotype between 
E9.0 and E11.5.  In the Smyd1 CKO, septation does occur, however the septum is not 
normal.  Therefore, even if embryos are rescued through the septation process, Smyd1 









Ratio Expected Ratio 
WT 10 0.20 0.25 
Het 39 0.80 0.50 
MT 0 0.00 0.25 
Table 4.1  Nkx2.5-Cre induced Smyd1 CKOs are not viable.  Smyd1WT/Flox; Nkx2.5-Cre 
were crossed with Smyd1WT/KO; Nkx2.5-Cre.  Smyd1WT/WT ; Nkx2.5-Cre is referred to as 
WT and Smyd1Flox/KO; Nkx2.5-Cre is referred to as MT.  Both Smyd1KO/WT and 
Smyd1Flox/WT with the Cre are referred to as HET.  Litters were genotyped at weaning and 
observed numbers were recorded.  There were no significant reduction in litter size 
between birth and weaning. 
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Nkx2.5-Cre Mediated Smyd1 CKO Phenocopies skNAC 
Because Smyd1 has primarily been found to interact with a protein called skNAC 
in a muscle library yeast 2-hybrid [6] and a cardiac library yeast 2-hybrid [7], we 
analyzed the possibility that these genes have cooperative roles.  Smyd1 and skNAC are 
expressed in very similar patterns; both have restricted expression patterns that include 
the myocardium, somitic myotome, and muscle cells.  Smyd1 is expressed as early as 
E7.75 and through adulthood in the myocardium of the mouse heart and is found in the 
myotome of somites as early as E12.5 [10].  Reporter assays suggest that Smyd1 is 
expressed in somites as early as E9.0 [67].  Smyd1 expression continues in developing 
and adult muscle tissue.  skNAC expression is not detectable as early as Smyd1 
expression, but weak expression in the mouse looping heart is detectable by E8.5 
(Personal Communication, C. Park and D. Srivistava).  Cardiac expression of skNAC 
continues in the myocardium through adulthood.  Somitic myotome expression is 
detectable at E12.5 and muscle expression continues through adulthood.   
skNAC KO mice survive to adulthood, however, in non-Mendelian ratios.  
Approximately half of the skNAC knock out embryos displayed cardiac edema by E10.5 
and like the Smyd1 CKO, at E11.5, many skNAC KO embryos display pericardial edema, 
cardiac hemorrhaging, poor trabeculation, disorganized ventricular septum, and a thinned 
ventricular wall (Personal Communication, C. Park and D. Srivistava).  In collaboration 
with the Srivistava lab at UCSF, microarrays on skNAC deficient E11.5 mouse hearts that 
did not display cardiac dysfunction were performed and candidate genes were analyzed 
by qRT-PCR in both Smyd1 CKO and skNAC KO hearts.  Surprisingly, only 23 genes 
were significantly deregulated in skNAC null hearts.  Of these, 17 genes are characterized 
(Fig 4.6A).  Most targets were also misregulated in the Nkx2.5-Cre induced Smyd1 CKO 
(Fig 4.6B). 
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Myoglobin, which is a cytoplasmic hemoprotein expressed in cardiac and skeletal 
muscle is the most significantly down regulated gene with a 4 fold reduction in Smyd1 
CKOs and 2 fold reduction in skNAC KOs.  Myoglobin is a known transcriptional target 
of skNAC [9].   It has since been shown that the methylation of skNAC, hypothetically by 
Smyd1, is essential for skNAC to bind to the promoter of Myoglobin (personal 
Communication L. Zhu, P. Tucker).  We also show that hydroxymethylbilane synthase 
(Hmbs) and erythroid differentiation regulator 1 (Erdr1), enzymes known for 
involvement in heme synthesis, were upregulated.  The fact that the heme transport 
protein, Myoglobin, was down regulated and heme synthesis enzymes, Hmbs and Erdr1, 
were upregulated, suggests that embryos are undergoing oxidative stress, which is also 
marked by the upregulation of anti-oxidants, Metallotheinein1, Metallotheinein 2, and 
Vanin1.  However, Vanin1 is oppositely misregulated in the two knockout systems.  In 
the skNAC null, Vanin1 is overexpressed but in the Smyd1 CKO, Vanin1 is down 
regulated.  
Transcriptional factors such as Shox2 and elongation factor RNA polymerase II, as 
well as a voltage gated potassium channel, Kcne1, are also interesting targets discovered 
in this microarray.  Interestingly, skNAC levels were down regulated in the Smyd1 CKO.  
This indicates that skNAC works downstream of Smyd1 as well as parallel to Smyd1.  
Other known candidate genes were also analyzed in these mice.  Because Irx4 and Hand2 
were found to be misregulated in the conventional Smyd1 KO, these targets were 
confirmed in the less severe Smyd1 CKO as well as in the skNAC KO.  Irx4 was similarly 
downregulated in all 3 knockout systems.  However, Hand2 was only affected by the 
Smyd1 knockouts.  Whether or not this effect is direct, it demonstrates that Smyd1 has 
transcriptional effects independent of skNAC. 
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Fig 4.6  The 17 characterized gene targets discovered in microarrays of the skNAC 
knockout were confirmed to be differentially expressed in both the skNAC knockout 
and the Smyd1 knockdown.  (A) Differentially expressed genes in the skNAC–/– hearts. 
Microarray analysis was performed on three individual E11.5 hearts per genotype. Genes 
showing more than 1.5 fold change in expression are shown. (B) Quantitative real-time 
RT-PCR analysis for the hearts of skNAC and Smyd1 mutants. Data are presented as 
mean of each genotype (for skNAC–/– analysis, n=3 and for Smyd1 mutants, n=4). The 
error bars indicate the combined standard error. 
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4.3  αMHC-cre induced recombination of the Smyd1Flox locus occurs in the heart and 
gonad tissues and is embryonically lethal. 
αMHC-cre transgenic mice (FVB) were obtained from the laboratory of Michael 
Schneider at Baylor College of Medicine.  Recombination induced by αMHC-cre is 
specific to cardiac tissue in the mouse and to ventricular myocytes, but not in ventricular 
fibroblasts in primary cultures [76].  This transgene was later shown to be expressed in 
the ventricular and atrial myocardium as early as E8.5 [75].   The same breeding strategy 
described in the previous section was employed to create Smyd1Flox/KO;αMHC-Cre+/? 
mice (BL6.FVB.129 hybrids) as well as the following breeders of the same background: 
Smyd1Flox/+; αMHC-Cre+/? and Smyd1KO/WT; αMHC-Cre+/?.  Once this combination of 
alleles was obtained, these mice were only crossed to each other, thereby maintaining a 
similar and inbred, but non-isogenic, hybrid population that is distinct from the Nkx2.5-
Cre induced CKO line.  Interestingly, several of the Smyd1Flox/WT; αMHC-cre+/? breeders 
died prematurely between 3 and 7 months of age. 
 
Tissue Surveys on the Smyd1 Locus 
Like with the Nkx2.5-Cre line, we initially analyzed αMHC-Cre effeciency on 
DNA recombination of the Smyd1 locus in heterozygous mice.  With this line of Cre we 
saw no evidence of a reduced Flox band in any tissue (Fig. 4.7).  However there was a 
strong Floxdel band in the heart as well as a band in the gonads (Fig. 4.7).  Therefore, it 
appears that recombination is weakly occurring in the heart and also in gonads.  Gonads 
often display basal expression of a slew of otherwise restricted genes.  This particular Cre 
transgene may have integrated into a locus in which some basal expression is allowed in 
the gonads and therefore Cre can be expressed to induce some amount of recombination.  
Although Cre expression alone in the gonads should not affect Smyd1 biology due to the 
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lack of endogenous Smyd1 expression in the gonads, this could create error in genotyping 
assays.  If recombination occurs in germ cells the Floxdel allele may pass on to offspring 
and would escape detection by our standard genotyping assay.  If two of the other three 
potential alleles, Smyd1KO, Smyd1Flox, or Smyd1WT, are detected, this possibility is ruled 
out.  However, if only one allele is detected, it is assumed to be homozygous for that 
allele and, although Smyd1KO/KO and Smyd1KO/Floxdel are comparable, animals that are 
genotyped as Smyd1WT/WT or Smyd1Flox/Flox may actually be heterozygous for the 
Smyd1Floxdel allele.  These animals would then be heterozygous for a Smyd1 deficient 
allele.  Neither of these genotypes would be selected for breeding, but may be selected 
for control animals in experiments.   
 
Embryonic Lethality of αMHC-Cre mediated Smyd1 CKOs 
Despite weak recombination, in the first 96 pups (9 litters), zero conditional 
knockouts survived to weaning age, while five mice that contained the same Smyd1 
alleles, but were Cre negative survived to weaning age.  With the above mating scheme 
we would expect 3/16, or 18 total, to be αMHC-cre+/-; Smyd1Flox/KO and 1/16, or 6 of 96, 
to be Smyd1Flox/KO (Table 4.2).  Therefore, the Cre negative genotype is surviving at 
normal ratios, but the Cre induced conditional knockout is lethal.  Because we saw no 
reductions of litter size between birth and genotyping, it can be said that this conditional 
knockout is embryonically lethal.   
Several embryonic ages were briefly analyzed.  At E11.5, 2 CKO embryos out of 
11 were observed and 1 of these was viable.  With this mating we expected 25% CKOs, 
therefore this is not significantly different from the expected Mendelian ratio.  At E13.5, 
4 of 9 embryos were genotyped as CKOs and 2 of these were viable.  With this mating, 
we expected 12.5% (1 of 9) CKOs, therefore we observed well above Mendelian ratios of 
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this combination of alleles.  However, we saw expected ratios of each allele.  The sample 
number is likely too low to be significant.  At E16.5, Mendelian ratios were within the 
expected range, however, only one of four observed CKO embryos was viable.  The 
αMHC-cre induced Smyd1 knockout is embryonically lethal and displays a phenotype in 
some embryos by E13.5 and death is common by E16.5.  
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Fig 4.7  αMHC-cre induced recombination of Smyd1 occurs in the heart and gonads.  
DNA was prepared from the tissues of a heterozygous Smyd1 deleting mouse.  
Recombination was assayed in the upper panel and the positive control Flox/WT assay 
was assayed in the lower panel.   
 
 
Genotype Expected Ratio Observed Ratio 
Smyd1 WT 0.3750 0.52 
Smyd1 HET 0.4375 0.48 
Smyd1 MT 0.1875 0.00 
Table 4.2  αMHC-cre induced recombination of Smyd1 is not viable. Smyd1WT/Flox; 
αMHC-Cre were crossed with Smyd1WT/KO; αMHC-Cre.  From the first 9 crosses we 
obtained an N of 96.  Genotypes with two cardiac deficient Smyd1 alleles are referred to 
as MT, genotypes with one cardiac functional allele are referred to as HET and genotypes 
with two cardiac functional alleles are referred to as WT.  Litters were genotyped at 
weaning and observed numbers were recorded.  There were no significant reduction in 
litter size between birth and weaning. 
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 Discussion 
The cardiac phenotype of the Smyd1 conventional knockout is not due to a 
hypomorphic allele of a Smyd1-neomycin fusion protein because the same result is 
obtained when the neomycin cassette is removed.  The cardiac phenotype observed in the 
conventional knockout is due to the lack of Smyd1 in the cardiac chambers and likely the 
lack of Smyd1 in the ventricular chambers.  The αMHC-cre induced knockout occurs 
weakly in the myotome of the atria and ventricles.  While this knockdown is not efficient, 
it does cause heart defects which lead to lethality.  The Nkx2.5-cre induced knockout is a 
little stronger and occurs a half-day earlier, but is restricted to the cardiac ventricles 
during embryogenesis.  Although this knockdown does not exactly phenocopy the 
conventional Smyd1 knockout, many of the same defects are observed.  Unlike the 
conventional knockout, the Nkx2.5-cre induced conditional knockout does undergo 
ventricular septation, but this is process is deficient.  There is also poor trabeculation, 
enlarged chambers, and cardiac edema.  Therefore, the same processes are affected; it is 
likely that they are partially rescued due to partial expression of Smyd1.  It is also 
possible that deletion at E8.0 is not early enough to inhibit the effects of Smyd1.  A third 
possibility is that Smyd1 expressed in the cardiac atria or valves can act non-
autonomously on the cardiac ventricles and this effect in the Nkx2.5-cre knockdown is 
responsible for the partial rescue of the phenotype. 
While Smyd1 is expressed in cardiac atria and valves, these conditional 
knockdowns do not address the role of Smyd1 in these tissues.  Co-analysis of the skNAC 
conventional knockout with the Nkx2.5-cre induced Smyd1 knockout revealed that the 
role of Smyd1 in the cardiac ventricles between E8.0 and E11.5 is closely related to a 
known binding protein, skNAC.  The phenotype of this Smyd1 knockdown was more 
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penetrant at this age, however the phenotypic skNAC knockouts phenocopied the Smyd1 
knockdown.   
While it has been shown that Smyd1 and skNAC interact at the protein-protein 
level (Personal Communication, L. Zhu and P. Tucker), it was surprising to find that 
there was a reduction of skNAC transcript in the Smyd1 knockdown.  This suggests that 
there is also a transcriptional effect of Smyd1 on skNAC.  Not surprisingly, transcript 
levels of Myoglobin were significantly decreased in both knockouts.  Oxidative stress 
markers were also shown to be deregulated as would be expected with decreased levels of 
Myoglobin.  The levels of markers were not quite as high in Smyd1 knockdowns as in 
skNAC knockouts, however, this is expected as neither skNAC nor Smyd1 are completely 
knocked out in the Smyd1 knockdown.  This suggests that the severity of the Smyd1 
phenotype is not simply because Smyd1 depletion has a more complete effect, being 
upstream of skNAC, but rather that Smyd1 affects skNAC independent pathways. 
While previous studies have shown that Smyd1 affects the transcript levels of 
Hand2 and Irx4, Hand2 was only affected in the Smyd1 knockdown while Irx4 was 
affected in both systems.  This suggests that although Smyd1 may affect Hand2 via a 
skNAC pathway and Irx4 is downstream of Hand2, Smyd1 affects Irx4 independently of 
Hand2 and skNAC.  This further emphasizes the role of Smyd1 in skNAC independent 
pathways.   
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Chapter 5.  MyoG-Cre Induced Embryonic Skeletal Muscle Smyd1 Knockouts are 
Embryonic Lethal with Few Observed Changes in the Transcriptome 
 
MyoG-Cre mice were obtained from the Olson laboratory on the B6C3F1 strain, 
which is a first generation hybrid of C3H and C57Bl/6J.  Recombination induced by 
MyoG-Cre is initiated in anterior somites at E9.0.  By E9.5 expression is detected in all 
somites and is confined and maintained in muscle tissue throughout embryogenesis [77].  
The same breeding scheme described above was employed to create Smyd1Flox/KO; MyoG-
Cre+/? mice (BL6.FVB.129.C3H hybrids) as well as the following breeders of the same 
background: Smyd1Flox/WT; MyoG-Cre+/? and Smyd1KO/WT; MyoG-Cre+/?.  However, in 
order to avoid breeding Cre to homozygosity we began crossing the above genotypes 
with Cre negative mice harboring the Smyd1Flox and Smyd1KO alleles.  It later became 
apparent that Smyd1Flox/Flox; MyoG-Cre+/- and Smyd1Flox/KO; MyoG-Cre+/- displayed the 
same phenotype.  In order to simplify the number of genotypes created and to create 
higher numbers of interesting genotypes, we mated Smyd1Flox/Flox to Smyd1Flox/WT; MyoG-
Cre+/-.  These mice were only crossed to each other, thereby maintaining an inbred, but 
non-isogenic, hybrid population that is similar, but isolated from the other cre induced 
CKO lines. 
 
Tissue Surveys on the Smyd1 Locus 
As described above, we analyzed Cre effectivity on genomic DNA recombination 
of the Smyd1 locus in heterozygous mice.  As with other tissue surveys, there was no 
detectable deletion of the Flox allele compared to the WT allele.  However, there was a 
strong recombination band specifically in the skeletal muscle tissue (Fig. 5.1).   
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Fig. 5.1  MyoG-Cre induces recombination of Smyd1 specifically in muscle tissue.  
DNA was prepared from the tissues of a heterozygous Smyd1 deleting mouse.  
Recombination was assayed in the upper panel and the positive control Flox/WT assay 
was assayed in the lower panel. 
 73
Phenotype of MyoG-Cre mediated Smyd1 CKOs 
Surprisingly, of the first 350 pups weaned and genotyped, there were zero Smyd1 
conditional knockouts (Table 5.1).  Many dead pups were found during and shortly after 
birth, but significant numbers of pups did not disappear between postnatal day 1 and 
weaning.  The birth of a few litters was observed; conditional knockout pups were 
difficult births, likely because of an increased size due to extreme edema.  These pups 
were often crushed during the birthing process.  Those that were born intact did not show 
signs of movement or breathing.  Genotypic ratios for these litters were analyzed between 
E9.5 and E17.5 and no significant variance from the expected Mendelian ratios were 
observed (Table 5.2).  Fetuses were extracted at E18.5, an age at which they could be 
fostered and survive if viable.  However, unlike their littermates, MyoG-Cre induced 
CKOs at this age made no attempts at locomotion or breathing.  Therefore, these 
conditional knockouts are not dying simply due to birthing problems, but never show 
signs of life during late stage embryogenesis.  Whether or not the heart was pumping at 
this age was not determined, but without locomotion these embryos could never survive.  
Therefore, this conditional knockout is perinatal lethal. 
Embryos were analyzed from E11.5 through E18.5.  At E12.5 embryos appear 
normal after sectioning (data not shown).  Some embryos are outwardly abnormal as 
early as E13.5 and by E15.5 CKOs are easily discerned from littermates by eye.  These 
pups displayed a very striking edema most visible in the back and shoulder area.  In order 
to observe the skeletal muscle in these mice, pups at various ages were sectioned and 
compared to their littermates.  At E15.5, there were obviously fewer myogenic cells, 
although different muscle groups were affected differently.  The limbs of conditional 
Smyd1 knockouts contained fewer cells than controls and correspondingly showed 
weaker in situ hybridization for a Myogenin probe, a marker of cells of myogenic 
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lineages (Fig. 5.2A-B).  However, the pectoralis and the sternohyoid muscle were no 
longer represented in sections (Fig 5.2A-B).  Haematoxylin and eosin (H&E) stained 
cross-sections of the scapula region shows that the surrounding muscle cells are less 
dense and less organized (Fig. 5.2C-D).  Also, there is an appearance of very large 
multinucleated cells, which are likely myoblasts that have fused to become 
multinucleated, but have failed to elongate into myotubes (Fig. 5.2E-F).  The tongue 
displays the same phenotype as the shoulder muscle (Fig. 5.2G-J).  However, the 
masseter muscle appears totally normal (Fig. 5.2K-N).   
To determine whether the apparent lack of cells and cell density is due to a 
decrease in proliferation, sections were analyzed by immunohistochemistry for Ki67, a 
protein that is present in all active stages of the cell cycle, but absent in the quiescent 
stages [78].  There does not appear to be significant differences in Ki67 staining in 
muscle tissue (Fig. 5.3).  However, it does appear that the leading edge of proliferation in 
the tongue epithelium is lagging (Fig 5.3C-D) and the amount of brown adipose tissue 
(BAT) is increased as well as more densely stained (Fig. 5.3A-B).  While differences in 
tongue sections may be due to misshaped tongues, the excess brown adipose tissue can be 
confirmed in other sections (Fig. 5.2A-B).  We have also shown that C2C12 siRNA 
knockdowns of Smyd1 are richer in triglycerides, a product of white adipose tissue, than 
control cultures (personal communication, L. Zhu).   
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Genotype Expected Ratio Observed Ratio 
Smyd1 WT 0.30 0.38 
Smyd1 HET 0.50 0.62 
Smyd1 MT 0.20 0.00 
Table 5.1  Skeletal Muscle specific knock-down of Smyd1 is lethal prior to weaning. Various 
Smyd1Flox/KO/WT; MyoG-Cre crosses were made.  From these crosses we obtained an N of 
350.  We expect 20% of pups to be homozygous for Smyd1 deficient alleles, 50% of pups 
should be heterozygous and 30% should be wild type.  Litters were genotyped at weaning 
and observed numbers were recorded.  There were no significant reduction in litter size 
between birth and weaning. 
  
Age (DPC) Smyd1 MT Smyd1 HET Smyd1 WT Total 
9.5 5 11 6 22 
12.5 4 9 10 23 
13.5 2 3 3 8 
14.5 0 4 0 4 
15.5 6 11 8 25 
16.5 6 5 2 13 
17.5 2 4 3 9 
Totals 25 47 32 104 
     
Expected Ratio 0.25 0.5 0.25  
Observed Ratio 0.24 0.45 0.31  
 
Table 5.2  Skeletal Muscle specific knock-down of Smyd1 does not induce resorption.  
Smyd1WT/Flox; αMHC-Cre were crossed with Smyd1WT/KO; αMHC-Cre.  Smyd1WT/WT; 
αMHC-Cre is referred to as WT and Smyd1Flox/KO; αMHC-Cre is referred to as MT.  Both 
Smyd1KO/WT and Smyd1Flox/WT with the Cre are referred to as HET. 
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Fig. 5.2  Skeletal muscle development in 
the MyoG-Cre induced Smyd1 CKO is 
significantly derailed by E15.5.  A-N) H&E 
stained transverse sections.  Myogenin in situ 
hybridization (A, B) show that there are much 
fewer muscle cells in the KO (B) compared to 
the WT (A).  It also demonstrates that not all 
muscles are affected equally, e.g. the pectoral 
(white arrow) and sternohyoid (yellow arrow) 
muscles are unrepresented in the KO, the 
dorsal muscles (solid blue arrow) are 
significantly diminished, but other muscles, 
like limb muscles are clearly less affected.  
There also appears to be an excess of brown 
adipose tissue (blue and white arrow) in the 
KO.  Failure of the muscles to develop can 
also be seen with pure H&E stains (C-N).  C) 
WT Scapula, 10x, D) KO Scapula, 10x. 
E)WT scapula, 40x F) KO scapula 40x.  Here 
the cells do not appear to be elongating along 
the same plane as cells are doing in the WT.  
Also many cells are forming “myo-balls” in 
which they appear multinucleated, but are 
failing to elongate in the KO (black arrow) 
(G-J).  G) WT Tongue, 10x. H) KO tongue, 
10x.  I) WT tongue 40x J) KO tongue 40x.  
“Myo-balls” are also evident in the tongue.  
However, there do not appear to be problems 
in masseter muscle development (K-N).  K) WT masseter 10x L) KO masseter 10x M) 
WT masseter 40x N) KO masseter 40x.  
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Fig 5.3  Proliferation of Skeletal Muscle in MyoG-Cre induced Smyd1 knockouts is 
unaffected, but there are non-autonomous effects on BAT.  Brown adipose tissue (pink 
arrows) in the dorsal regions (A, B), shows less Ki67 staining in the WT (A) than the KO 
(B).  Also, the tongue (C, D) shows proliferation differences in the epidermal region at 
the tip.  This line of proliferation appears to lag in the KO (D) compared to the WT (C).  




In an attempt to identify pathways in which Smyd1 functions, I performed RT-
PCR to analyze the transcriptome.  Smyd1 is a putative histone methyl transferase and has 
displayed HDAC dependent effects on transcription in luciferase assays [10].  Therefore, 
it is likely an important transcriptional factor.  We decided to analyze the transcript pool 
just prior to observing the phenotype in an attempt to preclude secondary effects of 
Smyd1 on other transcription factors from our data sets.  By RT-PCR at E13.5, there is an 
obvious inverse correlation between Smyd1 transcripts and Cre transcripts (Fig. 5.4).  
Because the myogenic program was significantly derailed, the first analysis included the 
myogenic regulatory factors, including Myogenin, MyoD1, Myf5, and Myf6.  Surprisingly 
none of these factors appear to be affected at the transcriptional level (Fig. 5.4).  I have 
also analyzed UCP-1 and Cidea, markers of brown adipose tissue formation and found no 
differences (data not shown).  Most transcripts that were analyzed, including skNAC, 
Myoglobin, TpnIs, and MyHCIIa, are not affected.     
TNFα is known to have a role incorporating fatty acids into muscle tissue while 
there is a direct correlation between IL6 and fatty acid oxidation by skeletal muscle [79].  
Both of these are inflammatory cytokines that are involved in maintenance and 
differentiation of skeletal muscle.  TNFα plays a bipolar role in muscle regulation; in the 
absence of TNFα, myogenic differentiation is blocked by failure to activate p38 [80], 
however TNFα is also known to play a role during cachexia, or wasting atrophy [81].  
Over expression and knockdown experiments of IL6 show that myogenic markers, 
Myogenin, α-actin, and p21, are directly correlated to IL6 levels through both the 
p38/MAPK and NFκB pathways [82].  Although TNFα levels are highly variant in these 
mice, it does not appear to be dependent on levels of Smyd1 transcript (Fig. 5.5).  IL6 
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levels are tightly correlated to Smyd1 levels, however, opposite effects are observed in 
male versus female mice (Fig. 5.5).   
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Fig 5.4  Skeletal Muscle Smyd1 deficiency does not affect transcription levels of 
MRFs (Myogenic Regulatory Factors).  Limbs obtained from E13.5 embryos were 
homogenized in "Trizol" and genotyped for Cre, Smyd1, and gender.  Appropriate 
samples were used for reverse transcription and then RT-PCR.  Some samples that are 
genotypically Cre positive do not express well and therefore Smyd1 levels are not highly 
reduced (arrow and red box). 
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Fig 5.5  Transcript levels of TNFα and IL6 vary in Smyd1 deficient skeletal muscle.  
Limbs obtained from E13.5 embryos were homogenized in “Trizol” and genotyped for 
Cre, Smyd1, and gender.  Appropriate samples were used for reverse transcription and 
then RT-PCR.  Some samples that are genotypically Cre positive do not express well and 
therefore Smyd1 levels are not as highly reduced (arrow and red box).  TNFα transcripts 
do vary, but this is more dependent on gender than on Smyd1 levels.  IL6 transcripts vary 
dependent on Smyd1 levels, although different effects are observed in different genders.  
Smyd1 deficiency in males leads to increased levels of IL6 whereas Smyd1 deficiency in 
females leads to slightly decreased levels of IL6. 
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MyoG-Cre induced CKO Adult Survivors 
After several years of mating these mice and genotyping over 190 litters, I 
observed absolutely zero living post-natal MyoG-cre induced Smyd1 CKOs on this non-
isogenic background.  However, two of four litters produced by one particular mother-
son cross have yielded pups in which MyoG-cre induced Smyd1 CKOs survive and 
appear outwardly normal into adulthood.  With this particular cross Smyd1 CKOs do not 
survive at normal Mendelian ratios, however crosses from their progeny exceed 
expectations of Smyd1 CKOs (Fig. 5.6).   
Initially these mice were sacrificed and tissues were harvested for RNA and 
DNA.  DNA analysis revealed that a recombination event was indeed occurring at the 
Smyd1 locus and specific to muscle; however, this recombination was not complete (Fig. 
5.7).  It is obvious that this recombination event did affect Smyd1 expression at the RNA 
level (Fig. 5.8).  On occasion I have observed embryonic individuals that were 
genotypically Smyd1 CKOs, but that have had normal Smyd1 levels.  When Cre 
expression is analyzed, these embryos have expressed Cre, but not as highly as other age 
matched embryos (Fig. 5.4 and Fig 5.5).  It is possible that the random locus into which 
this Cre transgene integrated is affected by repressors or enhancers that vary in different 
strains of mice.  Because the mouse lines I am working with are not isogenic, over time 
this particular branch of this line of mice could have either lost or gained a genetic 
modification or homozygosity of a modification that delays Cre expression.  If this 
explanation is accurate, it maintains that Smyd1 is necessary for skeletal muscle 
development, but indicates that Smyd1 is not essential for maintaining normal function in 
uninjured, developed skeletal muscle.  Delayed deletion of Smyd1 will rescue the skeletal 
muscle Smyd1 conditional knockout mice. 
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Data obtained from siRNA knockdowns of Smyd1 in C2C12 has suggested that 
Smyd1 has an effect on Calcineurin regulation of slow fiber formation (Personal 
Communication, L. Zhu).  Adult versions of the Smyd1 muscle CKO allowed us to not 
just dissect and analyze limb muscle, but to further dissect and analyze specific muscle 
groups of known fiber types.  The soleus muscle is composed primarily of slow muscle 
fibers, the tibialis anterior is primarily fast muscle fibers, and the gastrocnemius is a 
mixture of the two fiber types.  Isolates of these three muscle groups have been analyzed 
by RT-PCR to determine if there is a fiber-type switch.  It appears that the Smyd1 
knockdown is not as effective in the soleus muscle as in the gastrocnemius and the 
tibialis anterior.  This corresponds to levels of Cre expression (Fig. 5.8).  Although the 
soleus represents a weak knockdown of Smyd1, there is a surprisingly strong effect on 
some markers.  As we would predict, the slow muscle markers, MyHC-1 and Tpn1s, are 
not detectable in the fast tibialis anterior muscle.  Although the hypothesis was that 
Smyd1 had a positive regulatory role on slow muscle formation, the slow muscle markers, 
Tpn1s, MyHC-1, and MyHCIIa do not appear to be affected in either the soleus or the 
tibialis anterior.  However, the glycolytic fast muscle myosin, MyHC-IIb, is up regulated 
in the slow soleus.  Surprisingly, the intermediate oxidative-glycolytic Myosin, MyHC-
IIx is decreased in the slow soleus of the Smyd1 knockdown mouse, but increased in the 




Fig 5.6  A heritable change has occurred in a portion of the skeletal muscle specific 
Smyd1 CKO mouse line allowing CKOs to survive.  Mice were bred in a non-gender 
specific manner by crossing Cre; Smyd1Flox/Flox mice to Smyd1Flox/Flox mice.  Two of four 
litters from a mother-son cross yielded a few conditional knockout pups.  Crosses from 
these lines produce CKO pups at or above expected Mendelian ratios.  Numbers 
represented are litter numbers or litter number- individual number.  Gray numbers are 
duplications necessary to show breeding with multiple partners. 
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 Fig 5.7  Recombination is occurring specifically in the skeletal muscle of the MyoG-
Cre positive Smyd1Flox/Flox survivors.  Mice were sacrificed and DNA was extracted 
from tissues and analyzed via PCR.  A recombination product is occurring specifically in 
skeletal muscle when both the Cre transgene and Smyd1Flox allele are present. 
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Fig 5.8  Slow/Fast fiber type composition is altered in adult Smyd1 deficient skeletal 
muscle.  Mice were sacrificed and tissues were homogenized in “Trizol” for RNA 
extraction, reverse transcription, and finally, RT-PCR analysis.  Proper isolation of slow 
vs. fast muscle is indicated by the lack of troponin1 slow and MyHC1 in the fast muscle.  
The heterozygous mouse represented on the left in all three columns does not express 
Smyd1 as highly as the heterozygous mouse represented in the middle.  The Smyd1 
knockdown is not as efficient in the soleus muscle compared to the others.  However, 
expression levels of MyHC2X and MyHC2B are altered in all three muscles.  In slow 
muscle MyHC2x is directly correlated to Smyd1 expression whereas in mixed and fast, 
MyHC2x is oppositely correlated to Smyd1 levels.  MyHC2B is oppositely correlated to 
Smyd1 in slow and fast tissues whereas it appears to be directly correlated to Smyd1 
levels in mixed tissue.  
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Discussion 
The phenotype of the Smyd1 conditional knockout is quite striking because only 
one previous single gene mouse knockout has caused such a severe phenotype in skeletal 
muscle tissue.  This phenotype was due to Myogenin deficiency, with which myoblasts 
appear normal, but differentiation from myoblasts to myotubes is blocked.  The Smyd1 
MyoG-cre induced knockout appears similar to the Myogenin knockout in many ways: 
while there are many myogenic cells, the appearance of myo-balls suggests that these 
cells are not properly elongating or differentiating into myotubes.  Because myogenic 
regulatory factors, or MRFs, have long been considered responsible for proper muscle 
development, these genes, including Myogenin, MyoD, Myf5, and Myf6, we originally 
hypothesized that the lack of Smyd1 disrupts myogenesis by affecting expression of one 
or several of these transcription factors.  The most likely explanation would be that 
Smyd1 serves as a muscle specific histone methyltransferase and globally affects the 
transcriptome.  However, there was no obvious change at the transcript level of MRFs or 
of many other genes, which is further evidenced by the lack of changes in microarray 
data set (data not shown).  The lack of changes in the transcriptome, suggests that 
perhaps the role of Smyd1 involves posttranslational effects. While we have shown that 
Smyd1 can methylate at least one non-histone protein, there is no evidence that any of the 
MRFs are methylated or otherwise posttranslationally modified in a manner which could 
be affected by Smyd1.   
It is possible that Smyd1 is involved in determining whether a cell will become 
muscle or adipose, involved in cross-talk with adipogenic energy stores, or involved in 
muscle absorption of nutrients.  For example, adipose tissue and muscle tissue share 
similar precursors, it has been well documented that both primary muscle cell cultures 
and muscle cell lines can be induced to differentiate into adipose cells if given the 
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appropriate signals [83].  Therefore, it is likely that there are molecular pathways 
controlling this fating process in vivo and possible that Smyd1 is involved in this 
pathway.  Likewise, if Smyd1 deficient muscle is incapable of signaling the break-down 
of BAT to release the metabolites, BAT would accumulate faster than in control 
embryos.  Neither of these hypotheses would explain why the proliferation marker, Ki67, 
stained BAT more densely; however an alternate explanation is that Smyd1 deficient 
muscle is unable to absorb nutrients.  In this case, the excess nutrients in the system could 
be adsorbed by the brown adipose, causing an abnormal proliferation and expansion of 
BAT. 
We have also observed that not all tissues are equally affected.  Trunk muscles are 
nearly ablated, forelimb muscles are disorganized and improperly differentiated, but 
muscles like the masseter are normal.  We have observed that muscles appear normal as 
late as E12.5, post migration from the somatic myotome.  However, it is possible that the 
differential effect occurs earlier than the visible effect and that there is an essential 
molecular event involving Smyd1 prior to this migration. 
The genetic variation created by crossing four inbred strains as well as the, until 
recently, 100% penetrance suggested that Smyd1 was required for muscle development in 
all mice and not in one or two specific backgrounds.  This idea was recently brought into 
question when adult skeletal muscle conditional knockouts were obtained.  Although the 
first generation of survivors did not present at expected Mendelian ratios, subsequent 
generations have.  Therefore, it is likely that a genetic change occurred allowing mice to 
survive.  While it is possible that this line of mice gained a modifier that no longer 
requires Smyd1 expression, I hypothesize that this is not the case and that Smyd1 is 
indeed essential in all backgrounds.  This hypothesis is supported by previous data in 
which embryos are genotypically Cre positive, but expression of Cre is very low and 
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likewise expression of Smyd1 is unaffected.  In other words, the random genetic change 
has delayed Cre expression allowing Smyd1 to be expressed through the critical stages. 
The adult conditional knockouts will allow many interesting experiments that the 
perinatal lethal line would not.  The excess fat observed in conditional knockouts 
suggests that there may be a defect in energy usage in Smyd1 deficient muscle.  In 
skeletal there are four types of myosin heavy chains, a slow oxidative MyHC1, a fast 
oxidative MyHC2A, a fast intermediate MyHC2X, and a fast glycolytic MYHC2B.   The 
ratios of these in particular muscle groups are influence by aerobic exercise, the more a 
specimen exercises, the more oxidative MyHCs will be present.  The type of MyHCs 
present dictates the energy pathways a muscle can use in order to utilize energy to 
contract.  Early analysis of adult muscles has attempted to determine whether Smyd1 
expression affects fiber type and therefore energy usage.  While this data does not 
completely coincide with data obtained from C2C12 siRNA knockdowns of Smyd1, it 
does support the idea that the lack of Smyd1 does affect the ratios of oxidative and 
glycolytic myosins.  For the first time, this suggests that Smyd1 does have an effect in 
adult skeletal muscle. 
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Chapter 6.  Adult Inducible Smyd1 Knockouts Suggest that Smyd1 Functions in 
Muscle Maintenance Pathways as well as Developmental Pathways. 
 
6.1  αMHC-cre-PR1 mediated Smyd1 adult heart conditional knockouts suffer 
premature lethality, likely from chronic heart failure. 
Several inducible versions of transgenic recombinases have been created that are 
controlled via drug administration.  For example, Cre fusion proteins have been used 
which require interaction with drugs in order to enter the nucleus.  Expression of these 
fusion proteins are easily directed by known tissue specific promoters, but the enzymatic 
action of Cre cannot occur until it is co-localized with DNA in the nucleus.  We obtained 
αMHC-Cre-PR1 transgenic mice (FVB) from the laboratory of Michael Schneider at 
Baylor College of Medicine.  This transgenic fusion protein is expressed in a cardiac 
specific manner and is fused to a mutated progesterone ligand, PR1, which should only 
enter the nucleus by binding a synthetic progesterone receptor called RU486.  The 
Schneider lab showed that recombination is specific to the heart and is induced by 
intraperitoneal injections of RU486 with minimal background until mice are 6 weeks of 
age [84]. 
Initial studies used the breeding scheme described above that avoids breeding the 
Cre transgene to homozygosity and creates Smyd1Flox/KO; αMHC-Cre-PR1+/- mice 
(BL6.FVB.129 hybrids), and Smyd1Flox/KO and Smyd1Flox/Flox mice as controls.  It later 
became apparent that both CKO genotypes displayed the same phenotype.  In order to 
simplify the breeding scheme, we mated Smyd1Flox/Flox mice to Smyd1Flox/Flox; MyoG-
Cre+/- mice to yield 50% CKOs and 50% Flox/Flox controls.  These mice were only 
crossed to each other, thereby maintaining an inbred, but non-isogenic, hybrid population 
that is similar, but isolated from other CKO lines. 
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Tissue Surveys on the Smyd1 Locus 
Recombination assays were performed at 4 weeks of age and recombination was 
detected only in hearts of mice that had received RU486 injections for 5 days, but not in 
mice that had received corn oil injections.  However, as before, there was no decrease in 
the Flox allele compared to the WT allele (data not shown).  Therefore recombination 
was not complete.   
 
Phenotype of αMHC-Cre-PR1 mediated Smyd1 CKOs 
Despite the fact that surveys suggest recombination was specific to the heart in 
the presence of RU486, mice that received either RU486 in corn oil or corn oil alone 
were symptomatic and frequently died.  Mice carrying the CKO genotype, but that had 
not received drugs began dying at three to four months of age.  DNA was harvested from 
individual tissues during autopsy of these mice and used to show that recombination was 
occurring and that it was heart specific (Fig. 6.1).  These mice, however, were not 
heterozygous for Smyd1WT.  Therefore, the Flox/WT assay was not an acceptable positive 
control.  Surprisingly, these mice displayed cardiac specific recombination despite the 
absence of RU486.  The great variation in levels of the PCR recombination product could 
signify a great variation in the ability of Cre to induce recombination or could be due to 
variable DNA samples as there was no positive control. 
I observed untreated mice of various genotypes from this lineage until 1 year of 
age, at which point they were sacrificed if they had not already died naturally.  Mice that 
were sacrificed for experiments were included in the study up until the time point they 
were sacrificed, at which point they were censored.  In the six control genotypes, 
including Smyd1KO/Flox, Smyd1Flox/Flox, Smyd1KO/WT, Smyd1KO/WT; αMHC-CrePR1+/-, 
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Smyd1Flox/WT, or Smyd1Flox/WT; αMHC-CrePR1+/-, over 75% of mice survived through the 
end of the study.  However, only 4% of CKO mice, αMHC-CrePR1+/-; Smyd1Flox/Flox or 
αMHC-CrePR1+/-; Smyd1Flox/KO, survived (Fig. 6.2).  The average age of death in the 
CKO population was 196 days and the median age was 189 days (Fig. 6.3).  Although the 
mean and median are very close, the distribution does not appear to be normal.  Data 
from males and females were analyzed separately.  The average female death occurred at 
188 days, with a median of 193 days.  The average male death occurred at 201 days, with 
a median of 186.  The shape of the female curve had a left handed tail, whereas the shape 
of the male curve had a right handed tail (Fig. 6.4).  Although this trend is obvious when 
analyzing the data, there is no obvious analysis that leads to statistically relevant 
numbers.  While the differences in timing of death could be due to the effect of Smyd1 on 
different pathways in opposing genders, I believe that the most likely explanation is a 
difference between the genders in the ability of the Cre-PR1 fusion protein to enter the 
nucleus at different ages and knockdown Smyd1 levels in the absence of the synthetic 
progesterone receptor, RU486.  Regardless of the cause, all experiments were both age 
and gender matched to ensure that results would not be masked due to a possible 
difference in pathology between the two genders.     
Despite this separation, there was still a lot of variability within each group for 
onset of disease and phenotype.  Therefore, determining which ages to analyze was not a 
straight forward task.  Initial autopsies and transcript analysis was performed at early 
stages, mid stages and late stages in order to determine whether the loss of Smyd1 was 
occurring at early time points or whether it was likely that mice died shortly after the loss 
of the gene.  Based on the Kaplan-Meyer plot (Fig 6.2), I chose to use mice at 16 weeks, 
before death occurred, at 24 weeks, an age to which approximately half of the mice 
survived, and 32 weeks, an age at which mice could still be obtained with some 
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confidence.  Hearts for these animals were homogenized in “Trizol” and RNA isolates 
were reverse transcribed to analyze Smyd1 levels (Fig. 6.5).  There is a strong knockdown 
of Smyd1 at 16 weeks, which continues to decrease through 32 weeks.  Therefore, 
animals are not dying due to an acute loss of Smyd1, because there is a strong knock 
down well before the average age of death.  Therefore, it is likely that the loss of Smyd1 
is causing chronic heart disease.   
Although the age of phenotype onset was not predictable from mouse to mouse, 
CKO mice became outwardly distinguishable from their littermates before death.  
Common phenotypes included obesity, wasting, hunched backs, low range of motion, 
beady eyes, and quivering.  Upon dissection, phenotypic CKO mice typically had lower 
body weights, but increased heart weights (Fig. 6.6).  Although the increase percentage of 
heart weight was not statistically relevant, it is clear that the standard deviation of the 
conditional knockout data is increased (Fig. 6.6), suggesting that either body weight or 
heart weight may have a significant change.  Variability, and therefore standard 
deviation, may be increased because both obesity and wasting was observed as a general 
phenotype. When the number of variables was reduced to analyze only heart weight, 
there was a significant increase in heart weight in Smyd1 conditional knockout mice (Fig. 
6.7).  Sectioning the hearts shows that the diameter of the chambers is increased, however 
the gross muscle structure does not appear to be affected (Fig. 6.8).  An atrial thrombus 
was detected in the phenotypic mouse sectioned, although it is unclear if this is 
representative of all phenotypic CKOs. 
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Fig 6.1  αMHC-crePR1 induces recombination of the SmydFlox allele at varying levels 
specific to the heart.  Tissues were harvested from mice that had died naturally with no 
drug administration.  DNA extractions show that recombination had occurred specifically 
in the heart in at least two of the three mice.   
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Fig. 6.2  Mice with αMHC-cre-PR1 mediated Smyd1 deficiency have reduced life 
expectancies.  Mice were left untreated and observed for one year.  Those that were 
removed from the untreated population and subjected to experimentation were censored.  
Therefore the first value for N indicates the initial population size and the second value 
for N reflects the final population size, the N at 50 weeks.  Mice that died naturally at a 
midpoint were included in the total population size throughout the experiment. 
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Fig 6.3  The total population shows a normal Gaussian distribution for time of 
death, but when divided based on gender, the curves shift in opposite directions.  
Each point represents one mouse fatality.  Distribution of those clustered at the far right 
cannot be analyzed as they were artificially terminated at this point.  The boundary 
between the first and second quartile is denoted by the left side of the box, the boundary 
between the second and third quartile is denoted by the yellow median line, and the 
boundary between the third and fourth quartile is denoted by the right side of the box.  
The average is also noted.  Normal distribution is typically detected when both the 
average and median break the box into two equal segments.  The total CKO population 
(purple) appears to have a normal distribution, however the male CKO population (red) 
peaks on the left with a right hand tail and the female CKO population (blue) peaks on 
the right with a right hand tail.   
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Fig 6.4  The curves associated with male or female deaths do not show the same 
pattern.  A histogram was created for conditional knockouts of each gender based on 
two week intervals of age of death.  Percentage was calculated based on the raw number 
of deaths and the N during that interval.  Because N changes between intervals, 
percentages of each interval do not add up to 100%.  Trend lines were then overlaid on 
the histogram to examine the shape of the curve.  The highest percentages of males die at 
mid-stages, 24 weeks, whereas the highest percentages of females die at late stages, 38 
weeks.  Strikingly, no female has survived past 38 weeks whereas several males have 
survived past 52 weeks, the end of the study.
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Fig 6.5  Smyd1 is significantly knocked down before death occurs.  In order to 
compare the timing of death to the timing of the knockdown, animals were sacrificed to 
represent early, middle, and late stages of the plot depicted in Fig 6.2.  At 16 weeks there 
is a Smyd1 knockdown comparable to the knockdown seen in all other CKO systems.  By 
24 weeks this knockdown is very striking.  Assays were done with multiple cycle number 




Fig 6.6  The percent heart weight is not significantly changed, but is deregulated.  
Mice were sacrificed in eight different groups based on age give or take 1 week (23 to 25 
weeks and 33 to 35 weeks), gender and genotype.  Prior to sacrifice mice were weighed.  
In most animals the weight of the atria are negligible.  To allow for better blood removal, 
only the ventricles were isolated and weighed.  Average percentage is reported and error 
bars represent 1 standard deviation.  At 24 weeks, there is not a significant percentage 
change, but the error bars are increased.  It does not seem that this is due to an increased 
N as pooling males and females doubles the N, but does not affect the error bars.  
Although it is not significant, there is a change in average weight of hearts in 34 week old 
males.  When genders are pooled, this approaches significance.  Again the error bars are 
greatly increased, but are not affected in the wild type by pooling genders.  This suggests 
that regardless of whether there is a significant difference there is a deregulation of one or 
both of the variables.  With a higher N, this could become significant. 
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Fig 6.7  The heart weight is significantly changed in pooled 34 week old mice.  Mice 
were sacrificed in eight different groups based on age give or take 1 week (23 to 25 
weeks and 33 to 35 weeks), gender and genotype.  Prior to sacrifice mice were weighed.  
In most animals the weight of the atria are negligible.  To allow for better blood removal, 
only the ventricles were isolated and weighed.  Average weight is reported and error bars 
represent 1 standard deviation.  At 24 weeks, there is not a significant change, but the 
error bars are increased.  It does not seem that this is due to an increased N as pooling 
wild type males and females doubles the N, but does not affect the error bars.  There is a 
change in average weight of hearts in 34 week old males and females.  When genders are 
pooled, this becomes significance.  Again the error bars are greatly increased in the CKO, 
particularly in the males. 
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Fig. 6.8  Hearts 
of conditional 
knockout mice 






but no defects 
in the gross 
muscle struc-
ture.  The top 
panel represents 
a control Smyd1 
heterozygote; 
the middle 
panel represents a non-phenotypic Smyd1 conditional knockout, and the bottom panel 
represents a phenotypic Smyd1 conditional knockout.  The heart weights of the non-
phenotypic conditional knockout are increased compared to the control and the heart 
weight of the phenotypic animal was increased compared to both of the others.  Blood 
from the chambers was also more difficult to expel in the conditional knockouts 
evidenced by the blood pooling in the center of the ventricular chambers.  There is an 
atrial thrombosis (arrow) in the phenotypic heart.  The area within the right ventricular 
chamber is greatly increased in the both CKOs, the shape is of the left ventricle chamber 
is greatly circularized and the area is increased in the bottom panel.  The septum is 
thinned in both CKOs.  The left and right ventricular walls are thinned in the heart in the 
bottom panel.  However, there does not appear to be an effect on the gross muscular 
structure evidenced in the 400x photographs of the septum and the 630x photographs of 
the right ventricle.  RV: right ventricle, LV: left ventricle.
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Molecular Changes  
In order to determine which genes are affected by the knockdown and which 
genes are likely to be related to pathology, whole hearts from age matched males and 
females were subjected to RNA extraction, reverse transcription, and RT-PCR.  This has 
revealed that there is no clear trend in fluctuations of family members, Smyd2 and Smyd3.  
Irx4 and Hand2 were previously found to be deregulated in Smyd1 deficient embryonic 
cardiac tissue.  However, by RT-PCR analysis, only Hand2 transcripts appear to be 
affected in Smyd1 deficient adult heart tissues.  Hand2 is decreased in deficient hearts 
compared to controls (Fig. 6.9).  Because Mef2c was previously linked to the Smyd1 
pathway, albeit upstream, we confirmed that its expression was unaltered by RT-PCR.   
The same inflammatory cytokines discussed in chapter 6 are also known to have a 
role in adult cardiac disease, for example, TNFα has an immediate, early protective role 
against necrosis and apoptosis following induced cardiac injury [85], but over expression 
of TNFα leads to congestive heart failure [86] and knockouts of TNFα have an increased 
survival rate from induced myocardial infarction [87].  We found that while TNFα 
transcript levels were highly variant between individuals of this line, this did not appear 
to be dependent on Smyd1 levels (Fig. 6.9).  IL6 is another cytokine linked to cardiac 
disease and is directly correlated with mortality after myocardial infarction [88].  IL6 
transcript levels appear to be tightly correlated to Smyd1 levels when gender matching 
samples.  Surprisingly, this affect is opposite in different genders:  Smyd1 deficient males 
have increased levels of IL6 compared to controls while females have decreased levels of 
IL6 compared to controls (Fig. 6.9).   
Because there has recently been a connection between Smyd1 and regulation of 
the voltage gated potassium channel alpha sub-unit, Kv4.2, we analyzed transcript levels 
of KCND2, which encodes for Kv4.2.  Transcript levels of Kcnd2 displayed a decrease in 
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Smyd1 deficient adult heart tissue (Fig. 6.10).  Effects on potassium gradients along with 
the appearance of seemingly normal cardiac musculature suggest the possibility that 
animals are dying from arrhythmogenesis, an inability to respond to electrical stimuli, 
and not the hypothesized ventricular heart failure.  In order to address this, male 
littermates were sacrificed and cDNA pools were created from “Trizol” homogenates for 
the left ventricle and the right ventricle plus septum.  Prior to sacrifice, it was noted 
which animals were phenotypic Smyd1 CKOs, which were non-phenotypic CKOs, and 
which were Smyd1flox/flox controls.  The phenotypic CKO had extremely low levels of 
Smyd1 in both the left and right ventricle, whereas the non-phenotypic littermates have 
intermediate levels of Smyd1 in at least one ventricular chamber (Fig. 6.10).  Pools were 
analyzed for changes in atrial and brain natriuretic peptides, markers of hypertrophy and 
chronic heart failure.  Transcript levels of Atrial and Brain Natriuretic Peptides (ANP and 
BNP) were elevated in all CKO left ventricles compared to the control whereas ANP and 
BNP transcripts were increased in right ventricles corresponding to the severity of Smyd1 
knockdown (Fig. 6.10).  Kcnd2 and skNAC transcripts were also analyzed in individual 
ventricles.  Results from the Kcnd2 experiment coincide with previously mentioned data 




Fig 6.9  Hand2, Kcnd2, and IL6 transcripts are deregulated in Smyd1 deficient 
hearts.  RNA was isolated from hearts of 24 week old mice, reverse transcribed and 
analyzed via RT-PCR.  Levels of Smyd1 were decreased as expected in male mice.  
However the effect was much less striking in female animals.  Levels of Smyd2 and 
Smyd3 were not altered in correlation with Smyd1 expression level.  As observed in 
embryonic skeletal muscle CKOs, levels of IL6 were decreased in female CKOs and 
increased in male CKOs.  TNFα levels varied, but did not correlate to Smyd1 levels.  
Kcnd2 and Hand2 were moderately decreased in Smyd1 deficient hearts. 
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Fig 6.10  Phenotypic Smyd1 CKOs have significantly decreased levels of Smyd1, 
increased levels of natriuretic peptides, and decreased levels of skNAC and KCND2 
in both ventricles.  33 week old littermates were sacrificed.  The right ventricle and 
septum were homogenized together and the left ventricle was homogenized separately.  
RNA was isolated from both homogenates, reverse transcribed and analyzed via RT-
PCR.  -/- indicates animals that were Cre (+); Smyd1Flox/Flox.  +/+ indicates Cre (-); 
Smyd1Flox/Flox.  P indicates that the animal was phenotypic.  Levels of ANP and BNP in 
both ventricles corresponded inversely to Smyd1 levels.  Levels of skNAC and Kcnd2 
corresponded directly to Smyd1 levels.  The phenotypic animal had the greatest reduction 
in Smyd1 levels in both ventricles. The non-phenotypic have varying levels of Smyd1 in 
the right and left ventricles compared to the phenotypic and control animal.
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Discussion 
Although this system was not as tightly controlled by drug administration as 
initially intended, the results do provide a cardiac specific Smyd1 knockout that causes 
early lethality.  Due to the delayed onset of phenotype from the point of loss of Smyd1, 
these animals are likely suffering from chronic heart problems, such as chronic heart 
failure or arrhythmogenesis.  It is very rare for transgenic, knock-out, or knock-in mice to 
develop detectable chronic heart disease that ultimately results in early lethality without 
added stresses, such as electrical stimuli or invasive aortic banding procedures.  With 
further characterization, this line of mice may provide a model for studying adult onset 
cardiovascular disease.  I have shown that the heart weight in Smyd1 deficient mice is 
significantly increased.  I have also shown that Atrial and Brain Natriuretic Peptides, 
markers of hypertrophy and chronic heart failure, are increased in an inverse relationship 
with Smyd1. 
If these mice indeed suffer from chronic heart failure, it mimics human heart 
disease in that it is highly variable.  Like human populations, these mice have a varying 
mixed background which is likely to contribute to the variation in phenotype or timing of 
phenotype.  Genomic or proteomic analysis may lead to identifying other genetic or 
expression variables that play a role in adult onset cardiovascular disease. 
I have also shown that an alpha subunit of the potassium channel, which has 
previously been shown to be inhibited by cooperation of Smyd1 and Irx5, is decreased in 
the absence of Smyd1.  While this is counter-intuitive, the data shows that in the presence 
of only Smyd1 or Irx5, KCND2 is activated.  Irx5 is typically expressed in a gradient; 
therefore, much of the heart is void of Irx5.  In this tissue Smyd1 may typically activate 
Kcnd2.  I predict that we are detecting the lack of this activation.  Irx5 and Kcnd2 
expression levels should be further analyzed by immunohistochemistry and in situ 
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hybridization.  Sections of the cardiac muscle look normal, which suggests that mice may 
not be suffering from chronic heart failure.  An alternative possibility is that mice die due 
to arrhythmogenesis, an inability to interpret the body’s electrical signals that cause the 
heart to beat. 
In order to determine which disease or diseases these mice suffer from, mice 
should be physiologically tested.  Electrocardiograms can be performed before and after 
stimulus to determine if these mice have abnormal heart beats and if they exhibit 
abnormal tachycardia as seen in the Irx5 knockout mice.  Echocardiograms and invasive 
hemodynamics should also be used to determine whether the heart is beating and 
pumping blood through at normal pressures and volumes.  Mice should be tested for 
susceptibility to lowered air oxygen content by using hypoxia chambers or susceptibility 
to exercise induced hypoxia by using treadmills. 
 
 
6.2  Smyd1 adult skeletal muscle inducible knockout mediated by MLC-rtTA and 
Tet-On-Cre is not effective in all skeletal muscle tissues. 
Several inducible versions of transgenic recombinases have been created that are 
under control of drug sensitive promoters.  For example, the bacterial protein reverse 
tetracycline transactivator (rtTA) can, when activated by tetracycline or doxycycline, 
bind to DNA in a sequence specific manner and activate expression of adjacent genes 
[89].  Therefore, if you create a transgene in which the bacterial rtTA coding sequence is 
fused to a tissue specific promoter and Cre recombinase is fused to the bacterial rtTA 
sensitive operon (Tet-O), you can induce tissue specific expression of Cre by 
systematically introducing doxycycline.  Thus when both transgenes are combined with a 
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targeted homozygous floxed allele a tetracycline inducible conditional knockout is 
created. 
αMLC-rtTA transgenic mice and Tet-On-Cre mice were obtained from the 
laboratory of Mendel Rimer.  These were crossed onto the Smyd1Flox/KO line to obtain 
MLC-rtTA+/?;Tet-On-Cre+/?; Smyd1Flox/Flox and MLC-rtTA+/?;Tet-On-Cre+/?; Smyd1Flox/KO 
mice.  Because mouse hind limbs are so much more muscular than forelimbs, RT-PCR 
was initially performed using hind limb tissue in mice that had received doxycycline vs. 
mice that had only received vehicle.  However, Smyd1 transcript levels were not 
decreased in the hind limbs from doxycycline treated mice.  The Rimer lab observed 
varying levels of efficiency in different muscle groups, the most highly affected tissues 
were the forelimb and the tibialis anterior of the hind limb [90].  When forelimbs were 
analyzed for recombination, the knockdown was obvious (Fig. 6.11). 
The transactivator of this Cre is not effective in all skeletal muscle groups.  
Therefore, the lack of a phenotype does not mean that Smyd1 is not essential in adult 
skeletal muscle.  Also, we were not able to analyze effects in slow vs. fast muscle 
because the soleus, the only primarily slow twitch skeletal muscle in the mouse, is not 
affected.  Attempts at adapting the protocol to create primary myoblasts from forelimbs 




Fig 6.11  Animals treated with Doxycycline have a significant Smyd1 knockdown in 
the forelimb, but not the hind limb.  Mice were given food with doxycycline additives 
and no alternatives for five days.  They were then returned to the regular food for a month 
before sacrifice.  A significant decrease in Smyd1 transcript was observed in cDNA made 
from the mouse forelimb of a Smyd1 deficient animal compared to a homozygote.  
However, there appears to be an increase in Smyd1 levels in cDNA made from the hind 
limb compared to a control that was Cre negative.
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Discussion 
While these mice had much potential for analyzing Smyd1 in adults and for 
creating primary cultures that could serve as inducible knockdowns, the knockout was 
not ubiquitous within skeletal muscle.  These complications retarded forward progress 
and the MyoG-cre induced adult Smyd1 knockouts may be better suited for future 
experiments.  
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Chapter 7.  Identification of Previously Uncharacterized Smyd1 Alternative Splice 
Isoforms 
 
The knockout strategy used for the Smyd1 conventional and conditional 
knockouts removes exons 2 and 3 as well as the intronic regions between and 
immediately adjacent.  Previous studies have reported that this strategy was effective for 
knocking out all splice forms created by the Smyd1 gene [10].  However, primers used to 
determine this were in exons one and four.  I independently performed RT-PCR with 
primers in exons one and six and obtained a product that was significantly smaller than 
the expected product.  By purifying and sequencing the observed product, I demonstrated 
that it represented a splice junction between Smyd1 exons one and six.   By PCR 
amplification on cDNA pools using primers that overlapped the start codon of Smyd1a/b 
and the 3’ UTR of Smyd1a/b, a form of Smyd1 that encodes exons 1, 6, 7, 8, 9, and 10 
was purified and cloned into an expression vector.  During the process of creating this 
clone, another alternative splice form was also discovered and cloned that encodes exons 
1, 5, 6, 7, 8, 9, and 10.   
In E15.5 embryonic limbs, I found a band that represents one or both of these 
transcripts in all samples that contained a Smyd1 deficient allele, but not when there was 
simply a Smyd1Flox allele in the absence of Cre (Fig. 7.1).  In an attempt to determine if 
this is an endogenous transcript, other cDNA pools were analyzed including normal and 
deficient, embryonic hearts, adult hearts, and adult limbs.  I found that the alternative 
splice form(s) were introduced in skeletal muscle and embryonic heart after Smyd1 
knockdown, however, expression was detected in the adult heart without a knockdown 
(Fig. 7.1). 
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When the putative protein gene product from the exon one to exon six splice form 
was computationally analyzed, the domain blast program was able to detect a 
rudimentary SET domain, similar to an outlier yeast SET domain.  If a protein is made by 
either of the newly discovered alternative splice products, they should be detectable by 
western blot with Smyd1 antibodies which were raised to the C-terminal portion of the 
protein.  However, no evidence of this protein product has ever been detected (Fig. 7.2).   
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 Fig 7.1  With the exception 
of the adult heart, where 
Smyd1 alternative splice 
forms exist endogenously, 
the previously undocument-
ed transcripts exist only in 
the presence of the Smyd1 
deficient alleles.  A) Smyd1a 
cDNA representing exons 
and relevant primers.  B) 
cDNA from several 
genotypes of MyoG-cre 
embryonic skeletal muscle.  
The top panel detects the full 
length version of all Smyd1 
isoforms.  There is a 600 
base pair difference between Smyd1a and the exon 1-6 splice variant, 1.8 and 1.2kb, 
respectively.  The splice variant should be preferentially amplified due to a short (1’) 
elongation period.  There is no alternative splice form in the Cre (-) Smyd1Flox/WT sample, 
although there is a strong product in the Cre(+); Smyd1Flox/WT, Cre(-); Smyd1KO/WT, and 
Cre(+); Smyd1Flox/Flox samples.  The middle and bottom panels should detect only the 
splice variant as the internal primer primes the splice junction.  There could be minimal 
forward priming on the WT allele as the 3’ end of both internal primers could anneal.  All 
samples that contain a defective Smyd1 allele are highly enriched for the splice junction 
product.  C) 1ATG/UTR4 reaction in deficient and wild type adult heart, adult skeletal 
muscle and embryonic heart.  The splice variant should be enriched due to having a 
limited elongation period and a shorter product.  All tissues that contain one or more 
deficient Smyd1 alleles are positive for the splice variant.  The adult heart is the only 
place that the splice variant has been detected endogenously. 
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Fig 7.2  Although, the Smyd1 monoclonal antibody detects Smyd1 splice variant 
encoded proteins, there is no evidence to suggest these proteins are expressed in 
vivo.  A) Western blot of transfected 293T cell whole cell extract.  The Smyd1 
monoclonal antibody detects Smyd1a as well as both splice variants.  B) Whole cell 
extracts from adult skeletal and adult cardiac tissue detect large amounts of Smyd1a 
and/or Smyd1b.  However, there is no evidence that the smaller splice variants exist.  RT-
PCR data suggests that the transcripts would be present in all five of these tissue.  Its 
possible that the protein exists in levels not detectable by western blot or that these 
transcripts do not encode a protein.  
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Discussion 
It is possible that some of the observed phenotypes discussed above are due to the 
over expresssion of these splice isoforms instead of the knockdown of the previously 
characterized gene products.  The fact that this isoform exists endogenously in the adult 
heart suggests that it functions in some manner.  Although we have no evidence that this 
transcript is translated into protein, it is possible that it escaped detection by expressing at 
low levels, having a short half life, or requiring some sort of cues or stimulation prior to 
translation.  If this protein is translated it is likely to have some methylation function as it 
does have a rudimentary SET domain.  However, it does not contain the MYND domain, 
which is thought to be important for binding the methylation substrate.  This gene 
product may act as a dominant negative as some protein-protein interactions are thought 
to occur in C-terminal tail, although it is unclear what the ultimate results are of these 
interactions.  Over expressing a natural dominant negative would only enhance our 
visualization of the Smyd1 deficient phenotype.  However, it is possible that this protein 
isoform has a separate function or that the transcript has a function, perhaps encoding a 
short RNA.  While the presence of these transcripts has been greatly ignored, they should 
continue to be considered as putatively playing a role in the observed phenotypes. 
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Chapter 8.  Discussion 
 
Many mouse knockouts have effects only in certain backgrounds.  Often a single 
cross to a different line will cause the phenotype to simply disappear.  The fact that the 
knockouts of Smyd1 have such pronounced effects on these highly variant backgrounds 
speaks that the role of Smyd1 is very essential and non-redundant.  However, this mixed 
background also adds many complications.  For example, the modulation of TNFα, 
Smyd2, and Smyd3 transcript levels was consistently seen.  However, these changes seem 
to be completely independent of Smyd1 levels.  It is possible that changes in levels of 
these transcripts, while not caused by the lack of Smyd1, compound the observed 
phenotype; mice with lower levels may be able to survive longer or be less phenotypic 
than mice with higher levels, or vice versa.  It is impossible to determine how many other 
variations exist from litter to litter or even within a single litter.  Likewise, I was very 
surprised to consistently detect varying levels of IL6 between males and females in both 
the adult heart and embryonic skeletal muscle.  The ability to analyze age and gender 
matched litter mates is a limiting factor.  Therefore, while the impact of this system is 
clear, increased numbers must be analyzed before drawing solid conclusions. 
It is obvious that Smyd1 is essential throughout the development of both cardiac 
and skeletal muscle.  Even on mixed backgrounds mice are incapable of surviving 
through critical stages of development when they are deficient in Smyd1 expression.  
Surprisingly, Smyd1 seems to be very essential to cardiac performance in adult mice.  
However, it is unclear how Smyd1 functions at the molecular level.  It is likely that 
Smyd1 functions through lysine methylation of histone or non-histone proteins, like the 
transcription factor skNAC.  It is possible that Smyd1 primarily acts in the canonical 
manner for SET domain containing proteins and is a histone methyltransferase.  
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However, although there is a change in global histone acetylation, it has not been possible 
to detect a global change in histone methylation in Smyd1 deficient cells compared to 
controls (personal communication, L. Zhu and P. Tucker) and we have not been able to 
detect many alterations in the transcription of many genes in any knockout or knockdown 
system.  Therefore it is becoming more and more suggestive that the primary role of 
Smyd1 may to regulate protein activities post translationally via protein methyltransferase 
activity. 
It is surprising that two different potassium channels have come into question in 
two different systems.  It seems equally unlikely that Smyd1 has a direct role on two 
unrelated potassium channel subunits, Kcne1 in embryonic heart and Kcnd2 in adult 
heart, or that Smyd1 has a global effect on the regulation of potassium channels, but both 
possibilities require further analysis.  Regardless, it seems that Smyd1 affects many 
independent pathways, the roles of the two characterized and two uncharacterized 
isoforms may need to be further separated before elucidation of the molecular mechanics 
can occur. 
In order to accomplish this, over expression studies of the two novel Smyd1 
isoforms should be performed to determine if they affect the ability of C2C12 myoblasts 
to differentiate or proliferate.  Over expression of all four isoforms can be studied in 
10T1/2 cells, which can be pushed to differentiate into myoblasts.  We should develop 
northern or in situ hybridization probes that are specific to each of the four isoforms.  It 
will be easy to differentiate Smyd1a and the exon one to five splice isoform because they 
contain unique nucleotide and protein sequences.  However, Smyd1b and the 1-6 splice 
isoform only differ from Smyd1a and the 1-5 splice isoform, respectively, by lacking the 
thirty-nine base pair exon five.  These two isoforms do not have unique sequences.  There 
are not currently antibodies that distinguish the individual isoforms.  Specific primers and 
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probes are contingent on the splice junction sequences that will not hybridize to isoforms 
that contain the short insert. 
Further studies should also incorporate the further characterization of the 
embryonic and adult MyoG-cre induced skeletal muscle specific conditional knockouts 
and the αMHC-crePR1 induced adult heart specific conditional knockout.  Further 
hypotheses on the molecular basis of the phenotypes would be well guided by knowing 
whether both differentiation and proliferation were blocked in the embryonic forms, 
whether the satellite cells or cardiac stem cells were affected by the loss of Smyd1, and 
whether the adults are capable of responding to the electrical stimuli that causes 
contraction of both muscle types.  
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 Appendix 1:  Alphabetical Listing of all Transcription Factor Binding Site Hits on 
1kb of mmSmyd1 putative promoter 
Definitions:   
Opt:  Threshold Matrix Similarity, optimized for reducing background of each gene 
Position:  column 1 represents the range of nucleotides corresponding to the matrix 
binding site, nucleotides numbered in reverse fashion where 1 is 1006bp upstream of the 
transcription initiation site and 1006 is equal to the transcription initiation site, +1.  
Column 2 is the anchor point. 
Str: DNA strand 
Core Sim.:  ratio of matching nucleotides in the core binding sequence 
Matrix Sim:  ratio of matching nucleotides in the entire binding sequence 
Sequence: recognized DNA sequence, core sequence in capital letters 
Family/matrix Further 
Information 





V$AP1F/VMAF.01 v-Maf 0.82 386 -
 406 
396 (+) 1 0.826 acagcTGACatgggag
agaaa 




316 (-) 1 0.97 caagaCAGCtggattca 




389 (-) 1 0.979 catgtCAGCtgtgtctc 










261 (+) 1 0.83 agtttggTAGAaaggtc 









































































488 (+) 1 0.926 cttgcCACGgggagac
a 





857 (-) 1 0.93 aaaggCCAAtgaaga 




505 (+) 1 0.945 tagggTGGGggtggg 
V$ETSF/FLI.01 ETS family 
member FLI 
0.81 34 - 50 42 (+) 0.75 0.817 ataaCCAGaaatttaaa 
V$EVI1/EVI1.02 Ecotropic viral 




816 (-) 1 0.851 cacccagaaAAGAcac
c 
V$EVI1/EVI1.04 Ecotropic viral 
integration site 1 
encoded factor 
0.77 23 - 39 31 (-) 0.8 0.804 gGTTAtgtttagattct 
V$EVI1/EVI1.04 Ecotropic viral 




750 (-) 0.8 0.817 aGACAggatttgaaaac 
V$EVI1/EVI1.06 Ecotropic viral 




324 (-) 0.75 0.835 tggtgatacaAGACagc 
V$EVI1/EVI1.06 Ecotropic viral 
















0.95 46 - 62 54 (+) 1 0.955 ttaaaaaaAATActaca 
V$FKHD/XFD2.01 Xenopus fork 
head domain 
factor 2 
0.89 23 - 39 31 (+) 1 0.912 agaatcTAAAcataacc 
V$GATA/LMO2CO
M.02 
complex of Lmo2 
bound to Tal-1, 





120 (+) 1 0.961 gtaaGATAggcca 
V$GFI1/GFI1.01 Growth factor 
independence 1 






673 (-) 1 0.972 tgaAATCaagagcac 
V$GFI1/GfI1B.01 Growth factor 
independence 1 




697 (+) 0.75 0.82 gaaTATGaccgcagt 
V$HAML/AML1.01 runt-factor AML-1 1.00 772 -
 786 
779 (-) 1 1 ctagtgTGGTcctga 
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V$HAML/AML1.01 runt-factor AML-1 1.00 785 -
 799 
792 (+) 1 1 agcttgTGGTcattt 




266 (+) 1 0.933 AGAAaggtctg 
V$HMTB/MTBF.01 muscle-specific 
Mt binding site 
0.90 468 –
 476 
472 (+) 1 0.932 tgctATTTa 
V$HMTB/MTBF.01 muscle-specific 
Mt binding site 
0.90 647 -
 655 
651 (-) 1 0.901 ggctATTTt 
V$HMTB/MTBF.01 muscle-specific 
Mt binding site 
0.90 978 –
 986 
982 (-) 1 0.932 tgctATTTa 




863 (-) 0.75 0.849 ggagggAAAAggccaa
t 




































645 (-) 1 0.793 ctatttTTAGcctccag 






102 (-) 1 0.926 ttgaGGGAatggc 






923 (+) 1 0.982 agttGGGAagggg 
V$LEFF/LEF1.01 TCF/LEF-1, 























V$MAZF/MAZ.01 Myc associated 




188 (-) 1 0.903 tcagGAGGggcga 
V$MAZF/MAZ.01 Myc associated 




893 (+) 1 0.949 ggggGAGGtgagg 
V$MAZF/MAZR.01 MYC-associated 











0.80 21 - 43 32 (+) 1 0.847 ccagaatcTAAAcataa
ccagaa 




648 (+) 1 0.986 ctggaggctaaaAATAg
cctact 







0.90 39 - 61 50 (+) 1 0.904 cagaaattTAAAaaaaa
tactac 



















complex of Lmo2 
bound to Tal-1, 





636 (-) 1 0.98 cctcCAGGtgcctct 



















nuclear factor 1 
or related factors 
0.71 844 -
 872 




DNA binding site 
for NEUROD1 







V$NF1F/NF1.01 Nuclear factor 1 0.94 854 -
 872 
863 (+) 1 0.942 catTGGCcttttccctcct 
V$NFKB/CREL.01 c-Rel 0.91 92 -
 106 
99 (+) 1 0.947 aagggccaTTCCctc 



















































693 (-) 0.98 0.905 ggtcatATTCagc 
V$PAX1/PAX1.01 Pax1 paired 
domain protein, 







869 (+) 0.75 0.616 CCTTttccctcctgacac
a 




852 (-) 0.8 0.837 gaaaagGCCAatgaag
agtggccttacaa 













625 (+) 1 0.883 ctttTGATtgtcagagg 
V$PBXC/PBX1_M
EIS1.03 














758 (-) 0.75 0.781 atcctgacAGACaggat 




624 (-) 1 0.789 ctgaCAATcaaaa 
V$PCAT/ACAAT.0
1 




881 (-) 0.75 0.866 tccaCCACtgt 





















726 (+) 1 0.84 atgcTGGGagtatct 
V$RORA/NBRE.01 Monomers of the 






267 (+) 1 0.93 gtagaAAGGtctgggag 
V$RORA/NBRE.01 Monomers of the 














506 (-) 1 0.853 cCCCAcccccaccct 
V$SORY/SOX5.01 Sox-5 0.87 402 -
 418 
410 (+) 1 0.984 agaaaCAATgtcccttg 
V$SORY/SOX9.01 SOX (SRY-
related HMG box) 
0.90 1048 -
 1064 
1056 (+) 1 0.912 gatgaCAATaggcagc
a 



















104 (-) 1 0.904 taaggttgagGGAAtgg
cc 

















549 (-) 1 1 tGTCAga 
V$TALE/TGIF.01 TG-interacting 
factor belonging 





628 (+) 1 1 tGTCAga 
V$TBPF/ATATA.0
1 




736 (+) 1 0.816 gtatcttTAAGtgggtt 
V$TBPF/MTATA.0
1 
Muscle TATA box 0.84 37 - 53 45 (-) 1 0.853 tttttTAAAtttctggt 
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672 (-) 1 0.924 gaaatCAAGagcact 





507 (-) 1 0.976 ccccaCCCCcacc 





890 (-) 1 0.966 cacctCCCCctcc 
   from –
 to 
anchor     
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Appendix 2:  RT PCR primer pairs and conditions 






1700129I15Rik ggccctgaagctaactgaagac ggtttccttggagggcagag 65 36-41 169 
Actb tacgagggctatgctctc cgcagctcagtaacagtc 58-62 19-30 651 
Akt1 gccctggactacttgcac cgaacagcttctcgtggtcc 61 27-43 300 
AR caagctggagaacccattggac ggcagcaaaggaatctggttgg 55 35 897 
Calm4 gcagcagactgacatccagttg cacacccaaggaaaccatcctc 65 30-35 745 
CideA gcctgcaggaacttatcagc cacggccttgaagcttgtg 58 30 347 
Cre ggacatgttcagggatcgccaggcg gcataaccagtgaaacagcattgctg 60-62 20-35 268 
Cyr61 ggcatctccacacgagttacc ccgcatcttcacagttctggtc 60-65 30-40 268 
Gyltl1B cgtcgccagtgctctctatg cagctgaccactgcacactg 60 30-32 414 
Hand2 tacttccacggctggcttattg tcgttgctgctcactgtgcttt 62 35-36 467 
Igf1 cttctacctggcgctctgc gtcttgggcatgtcagtgtgg 61-61.4 27-43 300 
IL6 gccttcttgggactgatgc cgcactaggtttgccgag 60 27-35 604 
Irx4 tgctggccatcatcaccaagat ttggaccttggcgtttcagcat 62 35-36 666 
Irx5-2 caccaagatgaccctcaccc gtaataaagaggccgggacagc 60-62 34-36 763 
Isl1 tttctccggatttggagtggca atgcaagggactgagagggtct 62 35-40 359 
Kcnd2 tttcgtgcgcagtgtcatgagt aagttcgacacgatcacaggca 62 28-35 459 
Mafbx gtctgtgctggtgggcaac gcaaagctgcagggtgac 61 30-43 394 
Mdfi cggaagttgcagacgcatcc gagtccacagcactccatg 60-65 30-40 342 
Mef2c acagcaccaacaagctgttcca tgcttaaagagcaaccggagga 62 30-35 549 
MK2 gtgcctgctgattgtcatgg gatgacacccaaggaccac 60 30-32 361 
Murf1 ctcctgcagagtgaccaag gtcccaaagtcaatggccc 61 30-43 399 
Myf5 ttcggagcacacaaagctga aagctgctgttctttcggga 60 30-35 431 
Myf6 tgcgcgaaaggaggagac gaaaggcgctgaagactgc 60 32-35 379 
MyHCIIa 
(Myh2) 
cgaccctgaccgtgaaag tccggtgatcaggattga 60 38-40 335 
Myo6 gtggagcaggcaaacaatgctc cttcattaacacccaggccctc 60-65 36-40 280 
MyoD1 tgatgacccgtgtttcgact ttccctgttctgtgtcgctt 60 32-37 831 
MyoG aagcgcaggctcaagaaagt tcagttgggcatggtttcgt 60 30-35 426 
Mb ctcaccctgagaccctgg gtcattccggaagagctcc 60-65 30-37 330 
Myostatin gctggcccagtggatctaaatg gggtgtgtctgtcaccttgac 60 30-32 362 
p21 gcagatccacagcgatatccag ctaagggccctaccgtcctac 60 28-30 768 
p38 gagaacgtcattgggcttctgg gtgttgtttccattcgtccacgc 60 30-32 780 
PW1 catgagccgaagtgggagag gtggccttgtgtcatgtgag 60 25-32 399 
Serca2 ggcatctttgggcaggatg cctcaacagcagccacaatg 60 30-32 1239 
Serpini1 gtgatggatccaatgaggctgg gcacagccatcctactaatcgc 60-65 40-41 411 
skNAC ccagccgatcctcgtcaac ccttccttgccttcttctcac 60-65 29-37 260 
Smyd1(1-6) atggagaacgtggaggtcttc gctcacaggagcagtcaaagtag 60-62 25-29 816/424 
Smyd1(2-6) ctgcgggcagtgcaagtt gctcacaggagcagtcaaagtag 60-62 25-37 640 
Smyd1(4-6) caactgcaacggtttcactctcag gctcacaggagcagtcaaagtag 60-62 30 260/220 
Smyd1(6-9) acatagacttcctgcacctcagtg catgggtcaccaggagaatagcat 60-62 30 504 
Smyd1(7-9) cgagggtttgtatcacgaggttgt catgggtcaccaggagaatagcat 60-62 30 300 
Smyd2 ctggacaagctagacaacg tgatcttctgcccgtatttcaggg 62 28-32 700 
Smyd3 gagtcgtggcgtagtctgtgatc cagctgagacgcatcctggatc 62 28-32 360 
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Sprrl3 cactcaccttccgaggtatcc ctgccaccactgctacaac 65 36-41 365 
TNFa ggcctccctctcatcagttc gagatagcaaatcggctgacgg 60 25-35 293 
Tnni1 ggagcaggaacacgagga actggccgctccttttct 60 35-37 377 
UCP-1 gaaggtcagaatgcaagccc catggacatcgcacagcttg 58 30 364 
Zfp36 ccatggatctctctgccatctacg caggcctggttagggtctc 60 25-35 724 
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